BindingDB logo
myBDB logout

Search by Patent Identification


Patent: (prefix with "US" like US6078908)
PatentDataCompoundsHGNC
(for human-derived proteins)
Patent TitleOrganizationDepositionDownloads
US11208411 72 32 HGNC:11283 Compositions and methods for treating parasitic diseases The Regents of the University of California; Washington University 05/03/222D 3D TSV
US11208404 192 109 Compounds useful as inhibitors of ALCAT 1 PERENNA PHARMACEUTICALS, INC. 05/03/222D 3D TSV
US11208414 151 80 HGNC:8021 Ectonucleotidase inhibitors and methods of use thereof CALITHERA BIOSCIENCES, INC. 05/03/222D 3D TSV
US11208418 5 5 HGNC:7967 Nitrogenous tricyclic compounds and uses thereof in medicine SUNSHINE LAKE PHARMA CO., LTD. 05/03/222D 3D TSV
US11208696 31 31 HGNC:12401 Prognostic biomarkers for TTK inhibitor chemotherapy NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. 05/03/222D 3D TSV
US11208423 20 20 HGNC:8974 Pyridinamine-pyridone and pyrimidinamine- pyridone compounds Sprint Bioscience AB 05/03/222D 3D TSV
US11208403 267 122 HGNC:7027 Pyridone derivatives having tetrahydropyranylmethyl groups Daiichi Sankyo Company, Limited 05/03/222D 3D TSV
US11208416 42 41 HGNC:29652 Selective inhibitors of protein arginine methytransterase 5 (PRMT5) Prelude Therapeutics Incorporated 05/03/222D 3D TSV
US11208422 188 53 HGNC:6283 HGNC:6278 Substituted bridged diazepane derivatives and use thereof as TASK-1 and TASK-3 inhibitors Bayer Pharma Aktiengesellschaft; Bayer Aktiengesellschaft 05/03/222D 3D TSV
US11208415 416 376 HGNC:6943 HGNC:992 HGNC:990 Substituted indole Mcl-1 inhibitors Vanderbilt University 05/03/222D 3D TSV
US11207302 21 20 HGNC:6059 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase Incyte Corporation; Incyte Holdings Corporation 05/02/222D 3D TSV
US11208377 119 119 HGNC:1607 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof ALLERGAN, INC. 05/02/222D 3D TSV
US11208388 98 96 HGNC:1133 Certain chemical entities, compositions, and methods NEUPHARMA, INC 05/02/222D 3D TSV
US11207431 131 27 HGNC:4852 HGNC:14065 HGNC:14064 HGNC:19086 HGNC:14063 HGNC:14068 HGNC:14067 HGNC:13315 HGNC:4854 HGNC:4853 HGNC:18128 HDAC6 inhibitors and imaging agents The General Hospital Corporation 05/02/222D 3D TSV
US11208381 336 55 HGNC:8803 HGNC:3763 HGNC:6307 HGNC:8804 HGNC:3690 HGNC:3688 Indole derivatives and their use as protein kinase inhibitors RESPIVERT LIMITED 05/02/222D 3D TSV
US11207312 828 204 Metallo-beta-lactamase inhibitors and methods of use thereof Merck Sharp & Dohme Corp. 05/02/222D 3D TSV
US11208399 224 117 HGNC:5992 HGNC:11892 NLRP3 inflammasome inhibitors Novartis AG 05/02/222D 3D TSV
US11207298 596 595 Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators JANSSEN PHARMACEUTICA NV 05/02/222D 3D TSV
US11208400 567 526 Substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft 05/02/222D 3D TSV
US11208384 2 1 HGNC:12437 HGNC:4623 Sulfinylpyridines and their use in the treatment of cancer Oblique Therapeutics AB 05/02/222D 3D TSV
US11207325 709 243 HGNC:3188 Triazolopyrimidine compounds and uses thereof Novartis AG 05/02/222D 3D TSV
US11203594 66 28 HGNC:1773 Anti-proliferative agents for treating PAH Pfizer Inc. 04/29/222D 3D TSV
US11203595 52 13 Aza-indazole compounds for use in tendon and/or ligament injuries NOVARTIS AG 04/29/222D 3D TSV
US11203574 302 247 HGNC:6371 Human plasma kallikrein inhibitors BioCryst Pharmaceuticals, Inc. 04/29/222D 3D TSV
US11203586 38 37 Iridinesulfonamide compound and use method thereof Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Lianyungang Runzhong Pharmaceutical Co., Ltd.; Centaurus Biopharma Co., Ltd. 04/29/222D 3D TSV
US11203600 326 281 Kinase inhibitors and uses thereof DENALI THERAPEUTICS INC. 04/29/222D 3D TSV
US11202743 22 14 HGNC:3553 HGNC:2160 HGNC:2159 Personal care compositions comprising fatty acid amide derivatives Conopco, Inc. 04/29/222D 3D TSV
US11203591 304 302 HGNC:6863 Substituted 6-azabenzimidazole compounds Gilead Sciences, Inc. 04/29/222D 3D TSV
US11203571 100 100 HGNC:10582 Sulfonamides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED 04/29/222D 3D TSV
US11203601 38 19 HGNC:4617 HGNC:4616 Tricyclic compounds as glycogen synthase kinase 3 (GSK3) inhibitors and uses thereof The Broad Institute, Inc.; Biogen MA Inc. 04/29/222D 3D TSV
US11198699 72 56 HGNC:29652 Compounds targeting PRMT5 Aligos Therapeutics, Inc. 04/25/222D 3D TSV
US11198695 577 573 HGNC:7045 Fused ring derivative having MGAT-2 inhibitory activity SHIONOGI & CO., LTD. 04/25/222D 3D TSV
US11197867 468 113 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Aminopyrimidinyl compounds Pfizer Inc. 04/24/222D 3D TSV
US11197877 16 16 HGNC:10718 Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists GLYCOMIMETICS. INC. 04/24/222D 3D TSV
US11198681 192 115 HGNC:18368 Heteroaryl inhibitors of PAD4 Padlock Therapeutics, Inc. 04/24/222D 3D TSV
US11198691 188 92 HGNC:6371 HGNC:6357 N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors KalVista Pharmaceuticals Limited 04/24/222D 3D TSV
US11198680 42 13 HGNC:10251 HGNC:10252 Rho kinase inhibitor BA-1049 (R) and active metabolites thereof BioAxone BioSciences, Inc. 04/24/222D 3D TSV
US11192871 30 30 HGNC:5302 5-hydroxytryptamine receptor 7 activity modulators and their method of use Temple University-Of The Commonwealth System of Higher Education 04/17/222D 3D TSV
US11191762 118 111 HGNC:339 Alkyl substituted triazole compounds as agonists of the APJ Receptor AMGEN INC. 04/17/222D 3D TSV
USRE48841 739 377 HGNC:4849 HGNC:4848 Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators Janssen Pharmaceutica NV 04/17/222D 3D TSV
US11191732 9 8 Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy THE JOHNS HOPKINS UNIVERSITY 04/17/222D 3D TSV
US11191765 49 44 HGNC:17270 Heterocyclic compounds for the inhibition of PASK BioEnergenix LLC 04/17/222D 3D TSV
US11192861 302 246 HGNC:6371 Human plasma kallikrein inhibitors BioCryst Pharmaceuticals, Inc. 04/17/222D 3D TSV
US11192850 136 36 HGNC:9642 HGNC:9644 HGNC:9658 N-aryl oxamic acids Purdue Research Foundation 04/17/222D 3D TSV
US11192893 6 6 Pyrazoloquinazolinone antitumor agents The Rockefeller University 04/17/222D 3D TSV
US11192859 43 43 Quinoline compounds as modulators of RAGE activity and uses thereof TBA 04/17/222D 3D TSV
US11192880 4 4 Quinolone compounds as inhibitors of the BCL6 BTB domain protein-protein interaction and/or as BCL6 degraders ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) 04/17/222D 3D TSV
US11192900 103 68 Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors Nuvation Bio Inc. 04/17/222D 3D TSV
US11179399 92 88 HGNC:8974 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes SPRINT BIOSCIENCE AB 04/10/222D 3D TSV
US11186588 76 73 HGNC:7794 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative AYUMI PHARMACEUTICAL CORPORATION 04/10/222D 3D TSV
US11180460 40 40 HGNC:1133 Amino pyrimidine derivatives Novartis AG 04/10/222D 3D TSV
US11180482 48 46 HGNC:6863 Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors ARIAD Pharmaceuticals, Inc. 04/10/222D 3D TSV
US11180502 14 14 HGNC:10597 Azaspiro[4.5]decane derivatives and use thereof Purdue Pharma L.P. 04/10/222D 3D TSV
US11179370 8 8 Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers Jenrin Discovery, LLC 04/10/222D 3D TSV
US11186587 51 32 HGNC:85 HGNC:84 Compound as ACC inhibitor and use thereof NANJING SANHOME PHARMACEUTICAL CO., LTD. 04/10/222D 3D TSV
US11180455 172 161 HGNC:8156 Compounds for the treatment of pain TBA 04/10/222D 3D TSV
US11186580 8 4 HGNC:8978 HGNC:8977 Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor Incyte Corporation 04/10/222D 3D TSV
US11186589 106 95 HGNC:6853 Cyanoindoline derivatives as NIK inhibitors Janssen Pharmaceutica NV 04/10/222D 3D TSV
US11179397 147 145 HGNC:9644 Imidazopyrimidine derivatives Gilead Sciences, Inc. 04/10/222D 3D TSV
US11179389 39 38 Purine inhibitors of human phosphatidylinositol 3-kinase delta Merck Sharp & Dohme Corp. 04/10/222D 3D TSV
US11180484 295 59 HGNC:3530 HGNC:6371 HGNC:9475 HGNC:3529 HGNC:3535 HGNC:6357 Pyrazole derivatives as plasma kallikrein inhibitors KalVista Pharmaceuticals Limited 04/10/222D 3D TSV
US11186576 141 131 Pyrazolo[1,5-A][1,3,5]triazine and pyrazolo[1,5-A]pyrimidine derivatives as CDK inhibitors Aurigene Discovery Technologies Limited 04/10/222D 3D TSV
US11186590 23 23 HGNC:11331 Somatostatin modulators and uses thereof CRINETICS PHARMACEUTICALS, INC. 04/10/222D 3D TSV
US11186582 564 562 Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as PDE2 inhibitors Dart Neuroscience, (Cayman) LTD. 04/10/222D 3D TSV
US11180494 197 183 HGNC:6161 Substituted amino acids as integrin inhibitors Pliant Therapeutics, Inc. 04/10/222D 3D TSV
US11180471 516 254 HGNC:6371 HGNC:3529 Substituted oxopyridine derivatives Bayer Pharma Aktiengesellschaft 04/10/222D 3D TSV
US11186578 6 6 HGNC:1133 Substituted pyrrolo[3,2-d]pyrimidines and pyrazolo[4,3-d]pyrimidines as tyrosine kinase inhibitors Shenzhen TargetRx, Inc. 04/10/222D 3D TSV
US11186579 36 35 HGNC:6059 Therapeutic heterocyclic compounds Gilead Sciences, Inc. 04/10/222D 3D TSV
US11186577 549 212 HGNC:8529 HGNC:897 HGNC:895 HGNC:896 Vasopressin receptor antagonists and products and methods related thereto BLACKTHORN THERAPEUTICS, INC. 04/10/222D 3D TSV
US11180503 90 13 HGNC:8783 HGNC:8775 HGNC:8774 HGNC:8776 HGNC:8778 [1,2,4]Triazolo[4,3-A]pyrazin-6(5H)-one derivatives ELI LILLY AND COMPANY 04/10/222D 3D TSV
US11185537 69 27 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof Novartis AG 04/09/222D 3D TSV
US11185100 71 50 HGNC:15661 Methods for modulating taste receptors MARS, INCORPORATED 04/09/222D 3D TSV
US11186566 99 63 Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator Vertex Pharmaceuticals Incorporated 04/09/222D 3D TSV
US11186554 166 164 Non-fused tricyclic compounds VIVACE THERAPEUTICS, INC. 04/09/222D 3D TSV
US11186544 90 45 HGNC:3827 HGNC:3826 Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists Bristol-Myers Squibb Company 04/09/222D 3D TSV
US11173161 73 73 HGNC:19995 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 Takeda Pharmaceutical Company Limited 04/03/222D 3D TSV
US11173144 8 8 HGNC:290 Adrenergic receptor modulating compounds and methods of using the same The Board of Trustees of the Leland Stanford Junior University 04/03/222D 3D TSV
US11174254 34 17 HGNC:1133 HGNC:3236 Aniline-substituted 1,2-dihydropyrrol[3,4-C]pyridin/pyrimidin-3-one derivative and use thereof YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.; SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. 04/03/222D 3D TSV
US11174268 1277 333 HGNC:10593 HGNC:10585 HGNC:10596 Benzenesulfonamide compouds and their use as therapeutic agents Xenon Pharmaceuticals Inc. 04/03/222D 3D TSV
US11174245 334 124 Benzimidazole compounds and derivatives as EGFR inhibitors Boehringer Ingelheim International GmbH 04/03/222D 3D TSV
US11173162 856 187 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Bicyclic heterocycles as FGFR4 inhibitors Incyte Corporation 04/03/222D 3D TSV
US11173137 85 59 HGNC:281 HGNC:4598 HGNC:4597 HGNC:4596 HGNC:4594 HGNC:5286 HGNC:4593 HGNC:1954 HGNC:1953 HGNC:1950 HGNC:1952 HGNC:4600 Compositions and methods to modulate chloride ion channel activity The Board of Trustees of the Leland Stanford Junior University 04/03/222D 3D TSV
US11174262 18 18 Compounds, compositions and methods Denali Therapeutics Inc. 04/03/222D 3D TSV
US11174252 487 133 HGNC:1780 HGNC:1771 HGNC:1778 HGNC:1777 HGNC:1722 HGNC:1774 HGNC:1773 HGNC:8977 Heterocyclic compounds as kinase inhibitors NUVATION BIO INC. 04/03/222D 3D TSV
US11174248 32 29 Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof Merck Sharp & Dohme Corp. 04/03/222D 3D TSV
US11174244 634 303 HGNC:4617 HGNC:3091 Isoquinolin-3-yl carboxamides and preparation and use thereof BioSplice Therapeutics, Inc. 04/03/222D 3D TSV
US11174219 7 7 Neprilysin inhibitors Theravance Biopharma R&D IP, LLC 04/03/222D 3D TSV
US11174250 205 126 HGNC:12757 Substituted carboxamides as inhibitors of WDR5 protein-protein binding Propellon Therapeutics Inc. 04/03/222D 3D TSV
US11174232 95 89 Substituted heterocyclyl derivatives as CDK inhibitors Aurigene Discovery Technologies Limited 04/03/222D 3D TSV
US11174264 21 19 TYK2 inhibitors and uses thereof Nimbus Lakshmi, Inc. 04/03/222D 3D TSV
US10988505 14 5 HGNC:16517 Matriptase inhibitors and uses thereof SOCIÉTÉ DE COMMERCIALISATION DES PRODUITS DE LA RECHERCHE APPLIQUÉE SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. 03/30/222D 3D TSV
US11136328 48 11 HGNC:4586 HGNC:6251 HGNC:2625 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists Rugen Holdings (Cayman) Limited 03/27/222D 3D TSV
US11136312 309 71 HGNC:11330 HGNC:11331 HGNC:11334 HGNC:11332 HGNC:11333 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof Board of Trustees of the Southern Illinois University 03/27/222D 3D TSV
US11166958 20 20 HGNC:10478 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament Boehringer Ingelheim International GmbH 03/27/222D 3D TSV
US11168095 209 173 HGNC:6857 ASK1 inhibiting agents BIOGEN MA INC. 03/27/222D 3D TSV
US11136340 91 13 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:11393 HGNC:11390 HGNC:9413 HGNC:12401 Amino-triazolopyridine compounds and their use in treating cancer AstraZeneca AB 03/27/222D 3D TSV
US11168102 253 135 Bicyclic heteroaryl compounds and uses thereof Revolution Medicines, Inc. 03/27/222D 3D TSV
US11136315 35 35 HGNC:6027 CXCR2 antagonist MEDSHINE DISCOVERY INC. 03/27/222D 3D TSV
US11168075 35 34 HGNC:12805 Compounds and their use for reducing uric acid levels Acquist LLC 03/27/222D 3D TSV
US11168080 71 67 Dynamin-1-like protein inhibitors Mitobridge, Inc. 03/27/222D 3D TSV
US11136333 19 10 HGNC:76 Functionalized pyrano[2,3-D]pyrimidin-7-one derivatives and methods for their preparation and use The Texas A&M University System 03/27/222D 3D TSV
US11168089 34 34 HGNC:263 Fused pyrimidine derivatives as A2A / A2B inhibitors Incyte Corporation 03/27/222D 3D TSV
US11136320 25 25 HGNC:3691 Fused ring derivative used as FGFR4 inhibitor JACOBIO PHARMACEUTICALS CO., LTD. 03/27/222D 3D TSV
US11136311 221 214 HGNC:6853 Heteroaromatic derivatives as NIK inhibitors Janssen Pharmaceutica NV 03/27/222D 3D TSV
US11168069 12 6 HGNC:12437 HGNC:4623 Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer Oblique Therapeutics AB 03/27/222D 3D TSV
US11135210 8 8 HGNC:17635 Indane-amines as PD-L1 antagonists ChemoCentryx, Inc. 03/27/222D 3D TSV
US11168083 82 66 HGNC:6371 HGNC:9475 HGNC:3528 HGNC:3309 HGNC:3535 Inhibitors of Plasma Kallikrein and uses thereof Takeda Pharmaceutical Company Limited 03/27/222D 3D TSV
US11135207 42 42 HGNC:13709 Inhibitors of dihydroceramide desaturase for treating disease Centaurus Therapeutics 03/27/222D 3D TSV
US11166942 56 55 Inhibitors of integrated stress response pathway PRAXIS BIOTECH LLC 03/27/222D 3D TSV
US11136329 453 118 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 JAK inhibitors VIMALAN BIOSCIENCES, INC. 03/27/222D 3D TSV
US11136327 77 77 HGNC:3529 Macrocycles as factor XIA inhibitors Bristol-Myers Squibb Company 03/27/222D 3D TSV
US11136337 42 42 HGNC:8127 Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors Boehringer Ingelheim International GmbH 03/27/222D 3D TSV
US11168088 178 56 HGNC:1771 HGNC:1722 HGNC:1773 Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof TBA 03/27/222D 3D TSV
US11168082 96 95 HGNC:29079 Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors THE REGENTS OF THE UNIVERSITY OF MICHIGAN 03/27/222D 3D TSV
US11136325 20 7 HGNC:6857 HGNC:6858 Pyrrolopyrimidine and pyrrolopyridine derivatives GALAPAGOS NV 03/27/222D 3D TSV
US11136326 289 96 HGNC:6190 HGNC:7027 HGNC:12446 HGNC:8977 Pyrrolopyrimidine derivatives as TAM inhibitors Incyte Corporation 03/27/222D 3D TSV
US11136296 252 239 HGNC:9600 Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft 03/27/222D 3D TSV
US11136324 38 38 HGNC:6857 Substituted imidazoles as apoptosis signal regulating kinase 1 inhibitors Jiangsu Hansoh Pharmaceutical Group Co., Ltd.; Shanghai Hansoh Biomedical Co., Ltd. 03/27/222D 3D TSV
US11168090 232 115 HGNC:9967 Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors Array BioPharma Inc. 03/27/222D 3D TSV
US11168070 125 125 HGNC:2348 Therapeutic compounds and uses thereof GENENTECH, INC.; CONSTELLATION PHARMACEUTICALS, INC. 03/27/222D 3D TSV
US11168093 183 135 HGNC:10020 Thienopyridine inhibitors of RIPK2 Celgene Corporation 03/27/222D 3D TSV
US11136336 22 22 HGNC:497 Thienopyrimidones Boehringer Ingelheim International GmbH 03/27/222D 3D TSV
US11161839 234 186 2-quinolone derived inhibitors of BCL6 The Institute of Cancer Research: Royal Cancer Hospital; Cancer Research Technology Limited 03/20/222D 3D TSV
US11161835 15 15 HGNC:12805 Compounds and their use for reducing uric acid levels Acquist LLC 03/20/222D 3D TSV
US11161844 99 37 HGNC:18618 Cyclic substituted imidazo[4,5-c]quinoline derivatives PFIZER INC. 03/20/222D 3D TSV
US11161850 128 113 HGNC:263 Fused pyrazine derivatives as A2A / A2B inhibitors Incyte Corporation 03/20/222D 3D TSV
US11161838 26 13 HGNC:8978 HGNC:8977 Heterocyclic derivatives as PI3K inhibitors Incyte Corporation 03/20/222D 3D TSV
US11161815 65 33 HGNC:12437 HGNC:4623 Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer Oblique Therapeutics AB 03/20/222D 3D TSV
US11161854 111 77 Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof Merck Sharp & Dohme Corp. 03/20/222D 3D TSV
US11161849 6 6 HGNC:497 Inhibiting the transient receptor potential al ion channel Eli Lilly and Company 03/20/222D 3D TSV
US11161852 44 44 HGNC:13386 Inhibitors of NEK7 kinase HALIA THERAPEUTICS, INC. 03/20/222D 3D TSV
US11161848 544 530 HGNC:12607 Purinones as ubiquitin-specific protease 1 inhibitors FORMA Therapeutics, Inc. 03/20/222D 3D TSV
US11160797 364 48 Pyridinone derivatives and their use as selective ALK-2 inhibitors NOVARTIS AG 03/20/222D 3D TSV
US11161864 245 76 Sting agonists VENENUM BIODESIGN, LLC 03/20/222D 3D TSV
US11161855 196 97 Tricyclic fused thiophene derivatives as JAK inhibitors Incyte Corporation; Incyte Holdings Corporation 03/20/222D 3D TSV
US11155546 138 71 HGNC:1133 HGNC:3236 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives and uses thereof SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD.; YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. 03/13/222D 3D TSV
US11154544 4 4 HGNC:10597 Amide derivatives as Nav1.7 and Nav1.8 blockers RaQualia Pharma Inc. 03/13/222D 3D TSV
US11149022 66 66 HGNC:1953 Antagonists of the muscarinic acetylcholine receptor M4 Vanderbilt University 03/13/222D 3D TSV
US11149056 26 13 HGNC:4586 C7 substituted oxysterols and methods of use thereof SAGE THERAPEUTICS, INC. 03/13/222D 3D TSV
US11149013 2 2 HGNC:17989 Crystal form of urate transporter 1 inhibitor and preparation method and use thereof TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH CO., LTD. 03/13/222D 3D TSV
US11155532 130 129 HGNC:29079 Cyclopropylamines as LSD1 inhibitors Incyte Corporation 03/13/222D 3D TSV
US11155558 31 30 HGNC:8784 Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof TOPADUR PHARMA AG 03/13/222D 3D TSV
US11149009 37 35 HGNC:1338 Fused piperidinyl bicyclic and related compounds as modulators of C5A receptor InflaRx GmbH 03/13/222D 3D TSV
US11149040 75 38 HGNC:339 Fused triazole agonists of the APJ receptor Amgen Inc. 03/13/222D 3D TSV
US11155544 58 57 HGNC:1133 Heterocycle comprising tyrosine kinase inhibitors Principia Biopharma Inc. 03/13/222D 3D TSV
US11149020 100 46 HGNC:2452 HGNC:6876 MAP kinase modulators and uses thereof The Trustees of Columbia University in the City of New York; Northwestern University 03/13/222D 3D TSV
US11149054 314 157 HGNC:4586 Oxysterols and methods of use thereof SAGE THERAPEUTICS, INC. 03/13/222D 3D TSV
US11149292 1 1 HGNC:3165 Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof Arena Pharmaceuticals, Inc. 03/13/222D 3D TSV
US11149037 64 37 HGNC:3553 HGNC:17038 Pyrazole MAGL inhibitors H. LUNDBECK A/S 03/13/222D 3D TSV
US11155557 308 140 HGNC:6190 HGNC:6192 Pyrazolopyrimidine compounds and methods of use thereof Genentech, Inc. 03/13/222D 3D TSV
US11155556 68 17 HGNC:11393 HGNC:11390 HGNC:8973 HGNC:8975 HGNC:8977 HGNC:8976 Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders DANA-FARBER CANCER INSTITUTE, INC. 03/13/222D 3D TSV
US11149031 768 251 Substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof Sanofi 03/13/222D 3D TSV
US11149018 289 272 HGNC:9600 Substituted N-arylethyl-2-aminoquinoline-4-carboxamides and use thereof Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft 03/13/222D 3D TSV
US11149049 50 12 Substituted nucleosides, nucleotides and analogs thereof JANSSEN BIOPHARMA, INC. 03/13/222D 3D TSV
US11149023 140 70 HGNC:897 HGNC:895 Substituted triazole derivatives and uses thereof Bayer Pharma Aktiengesellschaft 03/13/222D 3D TSV
US11149067 112 33 HGNC:3309 HGNC:2521 Tailored cyclodepsipeptides as potent non-covalent serine protease inhibitors UNIVERSITÄT DUISBURG-ESSEN 03/13/222D 3D TSV
US11149066 15 15 Thrombospondin 1-binding peptide DAIICHI SANKYO COMPANY, LIMITED; PEPTIDREAM INC. 03/13/222D 3D TSV
US11147816 9 8 HGNC:6840 HGNC:6842 Composition for inducing differentiation and protection of neural stem cells and method for inducing neuro-regeneration using the same composition GENUV Inc. 03/12/222D 3D TSV
US11147877 20 17 Compositions and methods for treating CNS disorders Sage Therapeutics, Inc. 03/12/222D 3D TSV
US11149006 8 2 HGNC:11526 HGNC:11527 HGNC:11528 Compounds as neurokinin-1 receptor antagonists and uses thereof XWPHARMA LTD. 03/12/222D 3D TSV
US11147820 10 5 HGNC:3023 HGNC:3024 HGNC:3020 Methods for treating GI tract disorders NEUROGASTRX, INC. 03/12/222D 3D TSV
US11147801 29 29 HGNC:2867 Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors Aurigene Discovery Technologies Limited 03/12/222D 3D TSV
US11130745 268 215 HGNC:2867 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH BAYER AKTIENGELLSCHAFT; BAYER PHARMA AKTIEGELLSCHAFT; THE BROAD INSTITUTE INC.; PRESIDENT AND FELLOWS OF HARVARD COLLEGE; THE GENERAL HOSPITAL CORPORATION 03/08/222D 3D TSV
US11130759 752 715 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCE, INC. 03/08/222D 3D TSV
US11130767 38 38 HGNC:8977 Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors Incyte Corporation 03/08/222D 3D TSV
US11130750 27 15 HGNC:2637 HGNC:2625 Calcium channel inhibitors CAVION, INC. 03/08/222D 3D TSV
US11130748 79 78 Compounds MISSION THERAPEUTICS LIMITED 03/08/222D 3D TSV
US11129827 120 60 HGNC:3553 HGNC:17038 Dual MAGL and FAAH inhibitors Abide Therapeutics, Inc. 03/08/222D 3D TSV
US11129828 68 66 HGNC:2671 Pyridazinone compounds and their use as DAAO inhibitors Takeda Pharmaceutical Company Limited 03/08/222D 3D TSV
US11130769 312 308 HGNC:6943 Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein Prelude Therapeutics, Incorporated 03/08/222D 3D TSV
US11130740 19 17 HGNC:17635 Substituted 2,3-dihydro-1H-indene analogs and methods using same Arbutus Biopharma Corporation 03/08/222D 3D TSV
US11130754 97 95 HGNC:10020 Substituted benzamides as RIPK2 inhibitors Boehringer Ingelheim International GmbH 03/08/222D 3D TSV
US11142525 184 179 HGNC:6863 Azalactam compounds as HPK1 inhibitors PFIZER INC. 03/04/222D 3D TSV
US11141403 63 61 Benzimidazoles and indoles as taro inhibitors MERCK SHARP & DOHME CORP 03/04/222D 3D TSV
US11142505 71 58 HGNC:933 Compositions for APP-selective BACE inhibition and uses therefor The Regents of the University of California 03/04/222D 3D TSV
US11142531 15 13 HGNC:85 HGNC:84 Cyano substituted heteroarylpyrimidinone derivative, preparation method and use thereof ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. 03/04/222D 3D TSV
US11142527 99 99 Dihydropyrimidine compounds and uses thereof in medicine SUNSHINE LAKE PHARMA CO., LTD. 03/04/222D 3D TSV
US11142535 35 21 HGNC:4852 HGNC:11491 HGNC:14064 Heterocyclic compound as Syk inhibitor and/or Syk-HDAC dual inhibitor Hangzhou Innogate Pharma Co., Ltd. 03/04/222D 3D TSV
US11142507 105 35 HGNC:1780 HGNC:1771 HGNC:1778 Inhibitors of cyclin-dependent kinases Dana-Farber Cancer Institute, Inc. 03/04/222D 3D TSV
US11142520 74 37 HGNC:6541 HGNC:6535 LDHA activity inhibitors ARCTIC PHARMA AS 03/04/222D 3D TSV
US11141411 3 3 HGNC:9236 Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone Poxel SA 03/04/222D 3D TSV
US11141410 99 99 Oxazolidinones as taro inhibitors MERCK SHARP & DOHME CORP 03/04/222D 3D TSV
US11142526 224 187 HGNC:17038 Spirocycle compounds and methods of making and using same H. LUNDBECK A/S 03/04/222D 3D TSV
US11142524 61 51 HGNC:3356 Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics STINGRAY THERAPEUTICS, INC. 03/04/222D 3D TSV
US11117865 99 8 HGNC:2348 Inhibitors of bromodomain-containing protein 4 (BRD4) Board of Regents, The University Of Texas System 03/02/222D 3D TSV
US11124523 88 34 HGNC:6251 HGNC:2637 HGNC:8156 HGNC:2625 HGNC:2623 HGNC:2621 2,6-dioxaspiro [4,5] decane derivatives and preparation method therefor and pharmaceutical applications thereof TBA 02/26/222D 3D TSV
US11124510 50 24 HGNC:15631 HGNC:15632 Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof DYNAVAX TECHNOLOGIES CORPORATION 02/26/222D 3D TSV
US11117874 37 37 HGNC:2528 Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors ASTRAZENECA AB 02/26/222D 3D TSV
US11116764 6 3 HGNC:5301 Combination of pure 5-HT6 receptor antagonists with NMDA receptor antagonist Suven Life Sciences Limited 02/26/222D 3D TSV
US11117900 587 546 HGNC:882 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED 02/26/222D 3D TSV
US11124500 76 38 Disubstituted pyrazole compounds Eli Lilly and Company 02/26/222D 3D TSV
US11124511 34 33 Heterocyclic compounds as immunomodulators Incyte Corporation 02/26/222D 3D TSV
US11124496 7 7 HGNC:6857 Imidazolidine compounds Eli Lilly and Company 02/26/222D 3D TSV
US11124537 103 101 HGNC:7978 Inhibitors of glucocorticoid receptor ORIC PHARMACEUTICALS, INC. 02/26/222D 3D TSV
US11117891 4 4 HGNC:6857 Isoquinolin and naphthydrin compounds Eli Lilly and Company 02/26/222D 3D TSV
US11124504 383 184 HGNC:8154 HGNC:8156 Kappa opioid receptor antagonists and products and methods related thereto THE SCRIPPS RESEARCH INSTITUTE; BLACKTHORN THERAPEUTICS, INC. 02/26/222D 3D TSV
US11124518 28 28 HGNC:12761 L,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-one analogs Recurium IP Holdings, LLC 02/26/222D 3D TSV
US11116757 690 635 Methods and compositions of inhibiting DCN1-UBC12 interaction MEMORIAL SLOAN KETTERING CANCER CENTER; ST. JUDE CHILDREN''S RESEARCH HOSPITAL 02/26/222D 3D TSV
US11124538 66 62 Neuroactive steroids, compositions, and uses thereof Sage Therapeutics, Inc. 02/26/222D 3D TSV
US11117861 270 127 HGNC:3827 HGNC:3826 Phenylpyrrolidinone formyl peptide 2 receptor agonists Bristol-Myers Squibb Company 02/26/222D 3D TSV
US11117898 21 7 HGNC:2637 HGNC:2625 Pyrazolo-heteroaryl derivative, preparation method and medical use thereof Jiangsu Hengrui Medicine Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd. 02/26/222D 3D TSV
US11117892 40 39 HGNC:3091 Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases TBA 02/26/222D 3D TSV
US11117902 44 22 HGNC:3467 Selective estrogen receptor degraders Eli Lilly and Company 02/26/222D 3D TSV
US11124495 34 32 Tetrahydroisoquinolines and terahydronaphthyridines for the treatment of hepatitis B virus infection Hoffmann-La Roche, Inc. 02/26/222D 3D TSV
US11124509 50 50 Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment Clavius Pharmaceuticals, LLC. 02/26/222D 3D TSV
US11111253 170 117 HGNC:11364 HGNC:11362 6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity University of Pittsburgh—Of the Commonwealth System of Higher Education 02/22/222D 3D TSV
US11111270 105 39 HGNC:13702 Inhibitor of apoptosis protein (IAP) antagonists SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE 02/22/222D 3D TSV
US11111247 384 81 HGNC:3690 HGNC:3689 HGNC:3688 Pyrazolopyrimidine compounds and uses thereof Incyte Corporation 02/22/222D 3D TSV
US11111252 32 12 HGNC:3763 HGNC:2861 HGNC:6307 HGNC:8804 HGNC:3236 Pyrimidine compounds and pyrimido indole compounds and methods of use Duquesne University of The Holy Spirit 02/22/222D 3D TSV
US11124486 1232 1227 HGNC:8537 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same SHIONOGI & CO., LTD. 02/21/222D 3D TSV
US11111233 136 64 HGNC:3236 Amino pyrimidine compound for inhibiting protein tyrosine kinase activity Shenzhen TargetRx, Inc. 02/21/222D 3D TSV
US11124494 86 71 HGNC:3827 HGNC:3826 Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists Bristol-Myers Squibb Company 02/21/222D 3D TSV
US11124490 26 23 HGNC:10548 Autotaxin inhibitors UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION; UNIVERSITY OF MEMPHIS 02/21/222D 3D TSV
US11111237 256 250 HGNC:10894 Bicyclic compound and use thereof SK BIOPHARMACEUTICALS CO., LTD. 02/21/222D 3D TSV
US11111235 232 164 Compounds, compositions, and methods DENALI THERAPEUTICS INC. 02/21/222D 3D TSV
US11124489 76 53 HGNC:16629 HGNC:16626 EPAC antagonists Board of Regents, the University of Texas System 02/21/222D 3D TSV
US11110088 111 17 HGNC:3432 HGNC:3430 HGNC:1079 HGNC:1057 HGNC:1133 HGNC:6193 HGNC:6171 HGNC:11719 HGNC:12434 HGNC:3236 Imidazopyrazine inhibitors of Bruton's tyrosine kinase Acerta Pharma B.V. 02/21/222D 3D TSV
US11123311 64 62 HGNC:3402 Methods of treating mental disorders THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 02/21/222D 3D TSV
US11110095 106 43 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Pyrimidine compounds as JAK kinase inhibitors Theravance Biopharma R&D IP, LLC 02/21/222D 3D TSV
US11111242 611 315 HGNC:6193 Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides Pfizer Inc. 02/21/222D 3D TSV
US11111240 29 27 Sultam compound and application method thereof Chai Tai Tianqing Pharmaceutical Group Co., Ltd.; Lianyungang Runzhong Pharmaceutical Co., Ltd.; Centaurus Biopharma Co., Ltd. 02/21/222D 3D TSV
US11104680 85 27 HGNC:8775 HGNC:8774 HGNC:8776 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones as PDE1 inhibitors H. Lundbeck A/S 02/13/222D 3D TSV
US11104664 48 47 4,5,6-trisubstituted indazole derivatives, and preparation method and pharmaceutical use thereof TBA 02/13/222D 3D TSV
US11053244 3210 843 HGNC:15633 HGNC:15631 HGNC:15632 4-azaindole compounds Bristol-Myers Squibb Company 02/13/222D 3D TSV
US11104670 13 13 HGNC:4586 4-pyrimidin-5-ylmethyl-morpholine derivatives and the use thereof as medicament Boehringer Ingelheim International GmbH 02/13/222D 3D TSV
USRE48711 264 262 HGNC:6857 Apoptosis signal-regulating kinase inhibitors Gilead Sciences, Inc. 02/13/222D 3D TSV
US11053238 60 15 HGNC:1780 HGNC:1771 HGNC:1778 Benzimidazole derivatives, preparation methods and uses thereof BETTA PHARMACEUTICALS CO., LTD. 02/13/222D 3D TSV
US11104690 200 199 HGNC:16940 Indazole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 Merck Sharp & Dohme Corp. 02/13/222D 3D TSV
US11104668 20 20 HGNC:1133 Inhibitors of bruton's tyrosine kinase Hoffmann-La Roche Inc.; Chugai Pharmaceutical Co. 02/13/222D 3D TSV
US11053243 50 50 Inhibitors of hepatitis C virus replication Merck Sharp & Dohme Corp. 02/13/222D 3D TSV
US11103510 26 26 JAK1 pathway inhibitors for the treatment of cytokine-related disorders Incyte Corporation 02/13/222D 3D TSV
US11053226 703 379 KRAS G12C inhibitors and methods of using the same AMGEN INC. 02/13/222D 3D TSV
US11053253 229 223 HGNC:2771 Macrocyclic compounds for treatment of medical disorders Achillion Pharmaceuticals, Inc. 02/13/222D 3D TSV
US11104675 29 21 PTPN11 inhibitors NAVIRE PHARMA, INC. 02/13/222D 3D TSV
US11104676 1973 188 HGNC:7027 HGNC:12446 HGNC:7029 Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases Array BioPharma Inc. 02/13/222D 3D TSV
US11104665 14 14 HGNC:3357 Pyridazines Boehringer Ingelheim International GmbH 02/13/222D 3D TSV
US11053225 426 138 HGNC:7027 HGNC:12446 Pyrimidine derivative compound, optical isomer thereof, or pharmaceutically acceptable salt thereof, and composition for preventing or treating Tyro 3 related disease comprising same as active ingredient KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY 02/13/222D 3D TSV
US11053247 22 8 HGNC:6371 HGNC:3529 Pyrimidinones as factor XIA inhibitors Bristol-Myers Squibb Company 02/13/222D 3D TSV
US11053250 10 10 HGNC:17967 Pyrrolo[1,2-b]pyridazine derivatives Gilead Sciences, Inc. 02/13/222D 3D TSV
US11104682 6 2 HGNC:7027 HGNC:12446 Salts of TAM inhibitors Incyte Corporation 02/13/222D 3D TSV
US11053219 146 106 HGNC:6190 HGNC:6192 HGNC:12440 Substituted pyridines as TYK2 inhibitors Esker Therapeutics, Inc. 02/13/222D 3D TSV
US11053246 699 233 HGNC:3690 HGNC:3689 HGNC:3688 Substituted tricyclic compounds as FGFR inhibitors Incyte Corporation; Incyte Holdings Corporation 02/13/222D 3D TSV
US11053241 101 96 HGNC:12440 TYK2 inhibitors and uses thereof Nimbus Lakshmi, Inc. 02/13/222D 3D TSV
US11053242 166 156 HGNC:10935 [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11BH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto Neurocrine Biosciences, Inc. 02/13/222D 3D TSV
US11098029 75 71 HGNC:4849 5-alkyl pyrrolidine orexin receptor agonists Merck Sharp & Dohme Corp. 02/07/222D 3D TSV
US11098048 68 64 HGNC:10548 Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors Hoffmann-La Roche Inc. 02/07/222D 3D TSV
US11098058 163 149 Bicyclic ketone compounds and methods of use thereof Genentech, Inc. 02/07/222D 3D TSV
US11098063 264 113 HGNC:6283 HGNC:6278 Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft 02/07/222D 3D TSV
US11098045 462 116 HGNC:6834 HGNC:550 HGNC:6666 Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof Pharmaxis Ltd. 02/07/222D 3D TSV
US11098041 305 179 HGNC:1133 HGNC:6524 Heteroaryl compounds as BTK inhibitors and uses thereof Merck Patent GmbH 02/07/222D 3D TSV
US11098044 271 103 HGNC:18618 HGNC:76 Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders 1ST Biotherapeutics, Inc. 02/07/222D 3D TSV
US11098031 140 126 HGNC:9829 Inhibitors of RAF kinases KINNATE BIOPHARMA INC. 02/07/222D 3D TSV
US11098061 218 126 HGNC:6887 MK2 inhibitors and uses thereof Celgene CAR LLC 02/07/222D 3D TSV
US11098060 76 32 HGNC:8031 Macrocycle containing aminopyrazole and pyrimidine and pharmaceutical composition and use thereof CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.; CENTAURUS BIOPHARMA CO., LTD.; LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. 02/07/222D 3D TSV
US11098046 40 40 HGNC:8031 Macrocyclic compounds as TRK kinase inhibitors and uses thereof ANGEX PHARMACEUTICAL, INC. 02/07/222D 3D TSV
US11098059 60 26 HGNC:29652 PRMT5 inhibitors Merck Sharp & Dohme Corp. 02/07/222D 3D TSV
US11098034 4 4 HGNC:9602 Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto ARENA PHARMACEUTICALS, INC. 02/07/222D 3D TSV
US11053198 117 116 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED 02/06/222D 3D TSV
US11052087 10 10 Anti-HIV compounds Gilead Sciences, Inc. 02/06/222D 3D TSV
US11052093 334 184 HGNC:3527 Aryl-or heteroaryl-substituted benzene compounds Epizyme, Inc. 02/06/222D 3D TSV
US11052091 21 21 HGNC:9617 BRK inhibitory compound ONO PHARMACEUTICAL CO., LTD. 02/06/222D 3D TSV
US11053197 200 165 HGNC:1133 Carbazole derivatives Bristol-Myers Squibb Company 02/06/222D 3D TSV
US11096924 330 49 HGNC:16490 HGNC:18648 HGNC:3590 HGNC:3009 HGNC:14892 Combination therapies using immuno-dash inhibitors and PGE2 antagonists Trustees of Tufts College 02/06/222D 3D TSV
US11053216 207 36 HGNC:171 HGNC:1076 HGNC:172 HGNC:175 Compounds and methods of use Medivation Technologies LLC 02/06/222D 3D TSV
US11096942 94 47 HGNC:3236 Heterocyclic compounds and uses thereof Celgene CAR LLC 02/06/222D 3D TSV
US11053215 510 168 HGNC:19310 HGNC:8987 Heterocyclic compounds useful as Pim kinase inhibitors Incyte Corporation 02/06/222D 3D TSV
US11053207 20 18 HGNC:6059 Indoleamine-2,3-dioxygenase inhibitor and preparation method therefor Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences 02/06/222D 3D TSV
US11053213 252 252 Pharmaceutical compounds ALMAC DISCOVERY LIMITED 02/06/222D 3D TSV
US11096930 36 19 HGNC:11708 HGNC:6059 Substituted imidazopyridine compounds as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan-2,3-dioxygenase Merck Sharp & Dohme Corp.; IOmet Pharma Ltd. 02/06/222D 3D TSV
US11053196 26 26 Substituted indoline derivatives as dengue viral replication inhibitors Janssen Pharmaceuticals, Inc.; Kathalieke Universiteif Leuven 02/06/222D 3D TSV
US11059821 196 96 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins Incyte Corporation 02/02/222D 3D TSV
US11059825 184 129 HGNC:23692 CXCR7 antagonists ChemoCentryx, Inc. 02/02/222D 3D TSV
US11059827 25 25 HGNC:8031 Compounds and compositions useful for treating disorders related to NTRK Blueprint Medicines Corporation 02/02/222D 3D TSV
US11059830 16 10 HGNC:3711 Compounds that participate in cooperative binding and uses thereof Revolution Medicines, Inc. 02/02/222D 3D TSV
US11059858 61 60 Difluoroketamide derivatives as HtrA1 inhibitors Hoffmann-La Roche Inc. 02/02/222D 3D TSV
US11059828 739 376 HGNC:4849 HGNC:4848 Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators Janssen Pharmaceutica NV 02/02/222D 3D TSV
US11059822 25 25 HGNC:17038 MAGL inhibitors H. LUNDBECK A/S 02/02/222D 3D TSV
US11059834 25 24 Macrocyclic immunomodulators ChemoCentryx, Inc. 02/02/222D 3D TSV
US11059842 37 30 Monosaccharide amine and 3-nitro-2-phenyl-2H-chromene based inhibitors of glucose kinases University of South Carolina 02/02/222D 3D TSV
US11059823 60 15 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Small molecule inhibitors of the JAK family of kinases Janssen Pharmaceutica NV 02/02/222D 3D TSV
US11059824 30 30 HGNC:15631 Substituted purines as TLR7 agonists Primmune Therapeutics, Inc. 02/02/222D 3D TSV
US11059818 111 56 HGNC:7218 Triazolopyridine inhibitors of myeloperoxidase Bristol-Myers Squibb Company 02/02/222D 3D TSV
US11091488 78 78 1-cyano-pyrrolidine derivatives as inhibitors of USP30 MISSION THERAPEUTICS LIMITED 01/30/222D 3D TSV
US11091474 4 4 HGNC:11138 Alkoxy bis-heteroaryl derivatives as modulators of protein aggregation UCB Biopharma SRL 01/30/222D 3D TSV
US11091445 12 6 HGNC:7463 HGNC:7464 Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A. 01/30/222D 3D TSV
US11091444 12 7 HGNC:620 Hydantoins that modulate BACE-mediated app processing BUCK INSTITUTE FOR RESEARCH ON AGING 01/30/222D 3D TSV
US11091485 80 40 HGNC:1773 Imidazo[1′,2′:1,6]pyrido[2,3-d]pyrimidine compound as protein kinase inhibitor SHENGKE PHARMACEUTICALS (JIANGSU) LTD. 01/30/222D 3D TSV
US11091471 202 200 HGNC:6141 HGNC:4075 Isoxazolyl ether derivatives as GABAA α5 PAM Hoffmann-La Roche Inc. 01/30/222D 3D TSV
US11091482 63 63 HGNC:7967 Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators ARDELYX, INC. 01/30/222D 3D TSV
US11091472 200 113 HGNC:8978 HGNC:8984 HGNC:8973 HGNC:8972 HGNC:8983 HGNC:8975 PI-kinase inhibitors with anti-infective activity THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 01/30/222D 3D TSV
US11091476 215 46 HGNC:1771 Protein kinase inhibitors, preparation method and medical use thereof Gan & Lee Pharmaceuticals 01/30/222D 3D TSV
US11091451 142 70 HGNC:10850 SHMT inhibitors and uses thereof RAZE THERAPEUTICS, INC. 01/30/222D 3D TSV
US11091495 233 218 Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors MIRATI THERAPEUTICS, INC. 01/30/222D 3D TSV
US11091484 546 270 Tricyclic heterocycles as BET protein inhibitors Incyte Corporation 01/30/222D 3D TSV
US11084810 40 20 HGNC:2160 HGNC:2159 (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles Centrexion Therapeutics Corporation 01/24/222D 3D TSV
US11084821 27 27 Cyanopyrrolidine derivatives with activity as inhibitors of USP30 MISSION THERAPEUTICS LIMITED 01/24/222D 3D TSV
US11084809 188 92 HGNC:6371 HGNC:6357 N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors KalVista Pharmaceuticals Limited 01/24/222D 3D TSV
US11084808 111 107 HGNC:3529 Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof Jiangsu Hengrui Medicine Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd. 01/24/222D 3D TSV
US11084824 53 51 HGNC:1133 Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY 01/24/222D 3D TSV
US11084822 26 26 HGNC:6190 Salts and processes of preparing a PI3K inhibitor Incyte Corporation 01/24/222D 3D TSV
US11084823 100 51 HGNC:1133 HGNC:6193 Substituted pyrrolo[2,1-f][1,2,4]triazines as kinase inhibitors Daewoong Pharmaceutical Co., Ltd. 01/24/222D 3D TSV
US11084798 749 713 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. 01/23/222D 3D TSV
US11084800 569 565 HGNC:2771 Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders Achillion Pharmaceuticals, Inc. 01/23/222D 3D TSV
US11059811 43 33 Benzofuran derivative, preparation method thereof and use thereof in medicine Jiangsu Hengrui Medicine Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd. 01/23/222D 3D TSV
US11059766 16 6 HGNC:4597 Ethynyl derivatives Hoffmann-La Roche Inc. 01/23/222D 3D TSV
US11059794 142 70 HGNC:1373 HGNC:10548 Heterocyclic compounds useful as dual ATX/CA inhibitors Hoffmann-La Roche Inc. 01/23/222D 3D TSV
US11059792 28 28 HGNC:7873 Imidazolyl tricyclic enones as antioxidant inflammation modulators REATA PHARMACEUTICALS, INC. 01/23/222D 3D TSV
US11058688 252 122 Imidazopiperazine inhibitors of transcription activating proteins Board of Regents, The University of Texas System 01/23/222D 3D TSV
US11083720 9 9 Indazole inhibitors of fructokinase (KHK) and methods of use in treating KHK-mediated disorders or diseases Regents of the University of Colorado, a body corporate; Colorado Research Partners. LLC 01/23/222D 3D TSV
US11084793 121 118 HGNC:29079 Inhibitors of lysine specific demethylase-1 Celgene Quanticel Research, Inc. 01/23/222D 3D TSV
US11059789 98 21 HGNC:6190 HGNC:9380 HGNC:6192 HGNC:9393 HGNC:6193 HGNC:10251 HGNC:11892 HGNC:12440 HGNC:10252 HGNC:391 HGNC:5960 HGNC:9399 HGNC:9401 Isoquinoline-steroid conjugates and uses thereof Aerie Pharmaceuticals, Inc. 01/23/222D 3D TSV
US11059801 108 84 HGNC:2717 Methods to induce targeted protein degradation through bifunctional molecules DANA-FARBER CANCER INSTITUTE, INC. 01/23/222D 3D TSV
US11059784 85 31 HGNC:3167 HGNC:3165 Oxime ether compounds Bristol-Myers Squibb Company 01/23/222D 3D TSV
US11058676 21 21 HGNC:6666 Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof PHARMAKEA, INC. 01/23/222D 3D TSV
US11084784 7 7 ROR-gamma modulators and uses thereof PIRAMAL ENTERPRISES LIMITED 01/23/222D 3D TSV
US11058696 33 12 HGNC:3167 Substituted bicyclic compounds Bristol-Myers Squibb Company 01/23/222D 3D TSV
US11059809 7 7 Substituted cyanopyrrolidines with activity as DUB inhibitors MISSION THERAPEUTICS LIMITED 01/23/222D 3D TSV
US11078197 160 158 HGNC:10252 5-membered and bicyclic heterocyclic amides as inhibitors of rock Bristol-Myers Squibb Company 01/16/222D 3D TSV
US11077113 17 17 HGNC:8974 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes SPRINT BIOSCIENCE AB 01/16/222D 3D TSV
US11078206 26 14 HGNC:1133 HGNC:6193 Amino-fluoropiperidine derivatives as kinase inhibitor Daewoong Pharmaceutical Co., Ltd. 01/16/222D 3D TSV
US11078192 69 69 Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof TBA 01/16/222D 3D TSV
US11078188 39 39 HGNC:13575 Dihydroquinoxaline bromodomain recognition protein inhibitor, preparation method and use thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES 01/16/222D 3D TSV
US11078228 202 201 HGNC:8021 Ectonucleotidase inhibitors and methods of use thereof Calithera Biosciences, Inc. 01/16/222D 3D TSV
US11078182 32 32 Heteroaromatic compounds as Vanin inhibitors Boehringer Ingelheim International GmbH 01/16/222D 3D TSV
US11078196 13 13 HGNC:11138 Heteroaryl amides as inhibitors of protein aggregation UCB Biophama SRL 01/16/222D 3D TSV
US11078204 102 51 HGNC:8978 HGNC:8977 Heterocyclic derivatives as PI3K inhibitors Incyte Corporation 01/16/222D 3D TSV
US11078214 36 17 HGNC:2861 Monocyclic thieno, pyrido, and pyrrolo pyrimidine compounds and methods of use and manufacture of same Duquesne University of The Holy Spirit 01/16/222D 3D TSV
US11078199 159 155 HGNC:3688 Quinolone derivatives as fibroblast growth factor receptor inhibitors PRINCIPIA BIOPHARMA, INC. 01/16/222D 3D TSV
US11078186 177 155 ROR γ modulators Bristol-Myers Squibb Company 01/16/222D 3D TSV
US11077128 6 3 Selective inhibitors of Alpha2-containing isoforms of Na,K-ATPase and use thereof for reduction of intraocular pressure Yeda Research and Development Co. Ltd. 01/16/222D 3D TSV
US11078205 42 42 HGNC:10894 Selective inhibitors of protein arginine methlytransferase 5 (PRMT5) Prelude Therapeutics, Incorporated 01/16/222D 3D TSV
US11078201 837 819 HGNC:6863 Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists Nimbus Saturn, Inc. 01/16/222D 3D TSV
US11077100 354 354 HGNC:8537 Tetrahydroquinoline derivatives as P2X7 receptor antagonists RaQualia Pharma Inc.; Asahi Kasei Pharma Corporation 01/16/222D 3D TSV
US11077107 61 60 Triazolopyrazine TBA 01/16/222D 3D TSV
US11077111 8 2 Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals Bayer Animal Health GmbH 01/16/222D 3D TSV
US20200361871A1 233 229 HGNC:21625 COMPOUNDS Enterprise Therapeutics Ltd 01/13/222D 3D TSV
US11124497 463 179 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. 01/13/222D 3D TSV
US11072585 122 116 HGNC:6666 Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof PHARMAKEA, INC. 01/09/222D 3D TSV
US11071729 29 29 HGNC:4594 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones Addex Pharmaceuticals S.A.; Janssen Pharmaceuticals, Inc. 01/07/222D 3D TSV
US11071788 26 21 HGNC:6388 Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies BAYER PHARMA AKTIENGESELLSCHAFT 01/07/222D 3D TSV
US11071721 107 101 Bicyclic amide compounds and methods of use thereof Genentech, Inc. 01/07/222D 3D TSV
US11072617 225 223 Bicyclic sulfones and sulfoxides and methods of use thereof Genentech, Inc. 01/07/222D 3D TSV
US11072611 367 215 HGNC:3357 Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders GALAPAGOS NV 01/07/222D 3D TSV
US11072607 46 41 Inhibitors of RIP1 kinase and methods of use thereof Genentech, Inc. 01/07/222D 3D TSV
US11072619 39 13 HGNC:6190 HGNC:6192 HGNC:6193 Pyrazole[1,5-a] pyrimidine derivatives as kinase JAK inhibitors Celon Pharma S.A. 01/07/222D 3D TSV
US11072626 31 31 HGNC:6563 Small molecule inhibitors of Galectin-3 Bristol-Myers Squibb Company 01/07/222D 3D TSV
US11071730 205 201 HGNC:6863 Substituted 6-azabenzimidazole compounds Gilead Sciences, Inc. 01/07/222D 3D TSV
US11072582 277 275 HGNC:4501 Substituted pyrrolidines as G-protein coupled receptor 43 agonists Epics Therapeutics 01/07/222D 3D TSV
US11046714 161 146 HGNC:263 2,2-difluorodioxolo A2A receptor antagonists Merck Sharp & Dohme Corp. 12/28/212D 3D TSV
US11046713 40 19 HGNC:644 Androgen receptor modulating compounds ORION CORPORATION 12/28/212D 3D TSV
US11046725 52 26 HGNC:6561 HGNC:6563 Galactoside inhibitor of galectins GALECTO BIOTECH AB 12/28/212D 3D TSV
US11046712 181 175 HGNC:7056 Glycosidase inhibitors Asceneuron SA 12/28/212D 3D TSV
US11046702 199 198 HGNC:4597 Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same SK BIOPHARMACEUTICALS CO., LTD. 12/28/212D 3D TSV
US11046710 48 48 HGNC:438 Sulfonamide compounds Daiichi Sankyo Company, Limited; Sanford Burnham Prebys Medical Discovery Institute 12/28/212D 3D TSV
US11046662 48 45 HGNC:12716 HGNC:497 HGNC:18083 HGNC:17961 2-aryl-4-hydroxy-1,3-thiazole derivatives useful as TRPM8-inhibitors in treatment of neuralgia, pain, COPD and asthma DOMPÉ FARMACEUTICI S.P.A. 12/27/212D 3D TSV
US11046691 749 729 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. 12/27/212D 3D TSV
US11046646 10 5 HGNC:3167 HGNC:3165 Alkylphenyl compounds Bristol-Myers Squibb Company 12/27/212D 3D TSV
US11046658 260 127 HGNC:8978 HGNC:8977 Aminopyrazine derivatives as PI3K-γ inhibitors Incyte Corporation 12/27/212D 3D TSV
US11045455 135 26 HGNC:6190 HGNC:2596 HGNC:6192 HGNC:6193 HGNC:6251 HGNC:2637 HGNC:2625 HGNC:12440 Azetidine derivative, preparation method therefor, and use thereof SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. 12/27/212D 3D TSV
US11046649 149 148 HGNC:6059 Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase Board of Regents, The University of Texas System 12/27/212D 3D TSV
US11046671 26 12 HGNC:15631 HGNC:15632 Dihydropyrimidinyl benzazepine carboxamide compounds Hoffmann-La Roche Inc. 12/27/212D 3D TSV
US11046682 39 39 HGNC:6059 Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof Beijing Innocare Pharma Tech Co., Ltd 12/27/212D 3D TSV
US11046696 520 198 HGNC:9967 Fused pyrimidine compound or salt thereof Taiho Pharmaceutical Co., Ltd. 12/27/212D 3D TSV
US11046680 486 436 HGNC:339 Heteroaryl-substituted triazoles as APJ receptor agonists AMGEN INC. 12/27/212D 3D TSV
US11046652 39 36 Hydroxamic acids comprising pyrazole moiety and uses thereof HAWAII BIOTECH, INC. 12/27/212D 3D TSV
US11046672 414 70 HGNC:8803 HGNC:3763 HGNC:6307 HGNC:8804 HGNC:3690 HGNC:3688 Indolinones compounds and their use in the treatment of fibrotic diseases RespiVert Limited 12/27/212D 3D TSV
US11046688 205 202 HGNC:12401 Inhibitor compounds Cancer Research Technology Limited 12/27/212D 3D TSV
US11046651 75 35 HGNC:3023 HGNC:5295 HGNC:5182 Piperazine substituted azapine derivatives and uses thereof ALAIRION, INC. 12/27/212D 3D TSV
US11046670 63 27 HGNC:8157 Piperazinyl norbenzomorphan compounds and methods for using the same BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 12/27/212D 3D TSV
US11045448 41 41 HGNC:7010 Piperidines as covalent menin inhibitors THE REGENTS OF THE UNIVERSITY OF MICHIGAN 12/27/212D 3D TSV
US11045457 445 208 HGNC:11330 HGNC:11333 Piperidinyl-3-(aryloxy)propanamides and propanoates Takeda Pharmaceutical Company Limited 12/27/212D 3D TSV
US11046689 289 159 HGNC:6251 HGNC:3467 Selective estrogen receptor down-regulators AstraZeneca AB 12/27/212D 3D TSV
US11046675 8 8 Substituted isoquionline derivatives as immunomudulators Bristol-Myers Squibb Company 12/27/212D 3D TSV
US11046681 33 33 HGNC:12630 Substituted piperidines for the treatment of cancer LES LABORATOIRES SERVIER; VERNALIS (R&D) LTD 12/27/212D 3D TSV
US11046698 1366 1145 TYK2 inhibitors and uses thereof Nimbus Lakshmi, Inc. 12/27/212D 3D TSV
US11046686 30 30 HGNC:17967 Thiadiazole IRAK4 compounds Gilead Sciences, Inc. 12/27/212D 3D TSV
US11066365 273 271 1-cyano-pyrrolidine compounds as USP30 inhibitors Mission Therapeutics Limited 12/23/212D 3D TSV
US11066414 981 964 HGNC:3236 Cot modulators and methods of use thereof Gilead Sciences, Inc. 12/23/212D 3D TSV
US11066413 60 57 HGNC:263 Aminopyrimidine five-membered heterocyclic compound, and intermediate, preparation method, pharmaceutical composition and application thereof GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. 12/20/212D 3D TSV
US11066409 217 211 HGNC:8537 Bicyclic nitrogen-containing heterocyclic derivatives and pharmaceutical composition comprising the same SHIONOGI & CO., LTD. 12/20/212D 3D TSV
US11066404 6 6 HGNC:1771 Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors Incyte Corporation 12/20/212D 3D TSV
US11066406 60 15 Small molecule inhibitors of the JAK family of kinases Janssen Pharmaceutica NV 12/20/212D 3D TSV
US11066396 1453 478 HGNC:4852 HGNC:14064 HGNC:14068 HGNC:13315 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors MERCK SHARP & DOHME CORP. 12/19/212D 3D TSV
US11065253 471 329 HGNC:9413 Arylquinazolines MERCK PATENT GMBH 12/19/212D 3D TSV
US11065231 55 55 HGNC:17967 Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides ARVINAS OPERATIONS, INC. 12/19/212D 3D TSV
US11065249 32 26 HGNC:16940 Diacylglycerol acyl transferase 2 inhibitor Pfizer Inc. 12/19/212D 3D TSV
US11066360 104 102 HGNC:6371 Human plasma kallikrein inhibitors BioCryst Pharmaceuticals, Inc. 12/19/212D 3D TSV
US11066363 22 13 HGNC:11305 HGNC:11306 Substituted 6,11-dihydro-5H-benzo[B]carbazoles as inhibitors of ALK and SRPK DANA-FARBER CANCER INSTITUTE, INC. 12/19/212D 3D TSV
US11040966 1982 987 HGNC:4849 HGNC:4848 Benzimidazole-proline derivatives IDORSIA PHARMACEUTICALS LTD 12/14/212D 3D TSV
US11040034 272 135 HGNC:2592 HGNC:2591 Metalloenzyme inhibitor compounds PHASEBIO PHARMACEUTICALS, INC. 12/14/212D 3D TSV
US11041859 70 10 HGNC:17927 HGNC:30402 HGNC:23116 Methods of identifying SENP1 inhibitors CITY OF HOPE 12/14/212D 3D TSV
US11040968 17 17 HGNC:6857 Pyridine derivative as ASK1 inhibitor and preparation method and use thereof TBA 12/14/212D 3D TSV
US11040984 22 11 HGNC:3236 Quinazoline compound for EGFR inhibition MEDSHINE DISCOVERY INC. 12/14/212D 3D TSV
US11040980 33 32 HGNC:1133 Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors Principia Biopharma Inc. 12/14/212D 3D TSV
US11040979 20 4 HGNC:6342 Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR Blueprint Medicines Corporation 12/14/212D 3D TSV
US11040967 15 11 HGNC:12440 TYK2 inhibitors, uses, and methods for production thereof Nimbus Lakshmi, Inc. 12/14/212D 3D TSV
US11040970 54 42 HGNC:10935 VMAT2 inhibitor compounds and compositions thereof Neurocrine Biosciences, Inc. 12/14/212D 3D TSV
US11034715 248 146 HGNC:8021 Ectonucleotidase inhibitors and methods of use thereof Calithera Biosciences, Inc. 12/06/212D 3D TSV
US11034717 33 11 Farnesoid X receptor modulators Intercept Pharmaceuticals, Inc. 12/06/212D 3D TSV
US11034991 6 5 HGNC:29079 Methods to determine KDM1A target engagement and chemoprobes useful therefor Oryzon Genomics S.A. 12/06/212D 3D TSV
US11034671 100 99 HGNC:6857 Apoptosis signal-regulating kinase inhibitors and uses thereof SICHUAN HAISCO PHARMACEUTICAL CO., LTD. 12/05/212D 3D TSV
US11033547 127 100 HGNC:9644 Carboxamide-pyrimidine derivatives as SHP2 antagonists Merck Patent GmbH 12/05/212D 3D TSV
US11033539 1210 551 HGNC:1954 HGNC:1953 HGNC:1950 HGNC:1952 HGNC:1951 Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases Neurocrine Biosciences, Inc. 12/05/212D 3D TSV
US11034678 17 16 HGNC:16940 Diacylglycerol acyl transferase 2 inhibitors Pfizer Inc. 12/05/212D 3D TSV
US11034699 17 17 HGNC:4596 Ethynyl derivatives Hoffmann-La Roche Inc. 12/05/212D 3D TSV
US11034705 52 52 Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors Nikang Therapeutics, Inc. 12/05/212D 3D TSV
US11034692 420 390 HGNC:6863 Naphthyridines as inhibitors of HPK1 Genentech, Inc. 12/05/212D 3D TSV
US11034670 70 53 HGNC:270 HGNC:272 Poly-ADP ribose polymerase (PARP) inhibitors Mitobridge, Inc. 12/05/212D 3D TSV
US11034698 115 94 Pyrazolo[ 1,5a]pyrimidine derivatives as IRAK4 modulators Genentech, Inc. 12/05/212D 3D TSV
US11034658 65 65 Pyridinyl pyrazoles as modulators of RORγT Janssen Pharmaceutica NV 12/05/212D 3D TSV
US11034691 995 366 HGNC:3169 HGNC:3167 HGNC:3165 HGNC:14299 HGNC:3170 Sphinogosine-1 -phosphate receptor modulators for treatment of cardiopulmonary disorders THE SCRIPPS RESEARCH INSTITUTE 12/05/212D 3D TSV
US11034661 67 67 HGNC:6059 Substituted N′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase IDO inhibitors Merck Sharp & Dohme Corp. 12/05/212D 3D TSV
US11034694 837 825 HGNC:6863 Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists Nimbus Saturn, Inc. 12/05/212D 3D TSV
US11028054 35 35 HGNC:2867 1, 4, 6-trisubstituted-2-alkyl-1H-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors Merck Patent GmbH 11/29/212D 3D TSV
US11021493 720 166 HGNC:934 HGNC:2529 HGNC:933 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use Amgen Inc. 11/29/212D 3D TSV
US11026923 606 192 HGNC:8775 HGNC:8774 HGNC:8776 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors H. Lundbeck A/S 11/29/212D 3D TSV
US11028101 3 3 HGNC:10894 3-oxa-8-azabicyclo[3.2.1]octane derivatives and their use in the treatment of cancer and hemoglobinopathies CTXT PTY LTD 11/29/212D 3D TSV
US11028093 867 205 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors ARRAY BIOPHARMA INC.; CELGENE CORPORATION 11/29/212D 3D TSV
US11021475 37 35 Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses Bristol-Myers Squibb Company 11/29/212D 3D TSV
US11021511 20 6 Cyclic dinucleotides as sting agonists Janssen Biotech, Inc. 11/29/212D 3D TSV
US11028083 163 145 HGNC:23393 HGNC:18241 Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases Board of Regents, The University of Texas System 11/29/212D 3D TSV
US11026937 134 134 HGNC:18368 Heteroaryl inhibitors of PAD4 Padlock Therapeutics, Inc. 11/29/212D 3D TSV
US11028067 15 7 HGNC:12437 HGNC:4623 Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer Oblique Therapeutics AB 11/29/212D 3D TSV
US11028058 12 12 HGNC:263 Heterocyclic compounds as adenosine antagonists NUVATION BIO INC. 11/29/212D 3D TSV
US11021478 24 23 HGNC:1232 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL 11/29/212D 3D TSV
US11028066 97 97 HGNC:29079 Inhibitors of lysine specific demethylase-1 Celgene Quanticel Research, Inc. 11/29/212D 3D TSV
US11021467 405 131 HGNC:8978 HGNC:8980 HGNC:8977 Phosphatidylinositol 3-kinase inhibitors Gilead Sciences, Inc. 11/29/212D 3D TSV
US11026936 57 34 HGNC:8810 Piperidinyl-propanone derivatives Merck Patent GmbH 11/29/212D 3D TSV
US11028041 36 18 HGNC:5253 Second generation GRP94-selective inhibitors University of Kansas 11/29/212D 3D TSV
US11026958 41 36 HGNC:1960 Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors Merck Sharp & Dohme Corp. 11/29/212D 3D TSV
US11021481 837 812 HGNC:6863 Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists Nimbus Saturn, Inc. 11/29/212D 3D TSV
US11028085 837 823 HGNC:6863 Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as hpk1 antagonists Nimbus Saturn, Inc. 11/29/212D 3D TSV
US11028092 124 60 HGNC:8795 Substituted pyrazolo[3,4-d]pyrimidines as PDE9 inhibitors Merck Sharp & Dohme Corp. 11/29/212D 3D TSV
US11028080 44 36 Substituted pyrimidines as LRKK2 inhibitors DENALI THERAPEUTICS INC. 11/29/212D 3D TSV
US11028051 14 7 Tetrahydroquinoline-based bromodomain inhibitors St. Jude Children''s Research Hospital 11/29/212D 3D TSV
US11028075 182 90 HGNC:10597 Therapeutic compounds and methods of use thereof Genentech, Inc. 11/29/212D 3D TSV
US11021463 202 145 HGNC:6371 Therapeutic inhibitory compounds ATTUNE PHARMACEUTICALS, INC. 11/29/212D 3D TSV
US11021515 404 207 Therapeutically active compounds and their methods of use Agios Pharmaceuticals, Inc. 11/29/212D 3D TSV
US11028064 146 76 HGNC:6307 Tricyclic heterocyclic derivatives and uses thereof AUCKLAND UNISERVICES LIMITED 11/29/212D 3D TSV
US11028104 83 42 HGNC:12008 HGNC:20692 Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN; FORSCHUNGSVERBUND BERLIN E.V. 11/29/212D 3D TSV
US11028090 505 491 HGNC:13575 [1,2,4]Triazolo[4,3-a]quinoxaline derivative, method for preparing same, and pharmaceutical composition for preventing or treating BET protein-related diseases, containing same as active ingredient Dong Wha Pharm. Co., Ltd.; Korea Research Institute of Chemical Technology 11/29/212D 3D TSV
US11020398 376 299 HGNC:1133 Amino-pyrrolopyrimidinone compounds and methods of use thereof ArQule, Inc. 11/28/212D 3D TSV
US11020381 174 169 HGNC:10597 Biaryloxy derivatives as TTX-S blockers RaQualia Pharma Inc.; XuanZhu Pharma Co., Ltd. 11/28/212D 3D TSV
US11021457 150 150 Class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof WIGEN BIOMEDICINE TECHNOLOGY (SHANGHAI) CO., LTD. 11/28/212D 3D TSV
US11020397 70 44 HGNC:12805 HGNC:17989 Compounds and their use for reducing uric acid levels Acquist LLC 11/28/212D 3D TSV
US11020395 154 115 HGNC:339 Cycloalkyl substituted triazole compounds as agonists of the APJ receptor AMGEN INC. 11/28/212D 3D TSV
US11020380 410 396 HGNC:2348 Therapeutic compounds CELGENE QUANTICEL RESEARCH, INC. 11/28/212D 3D TSV
US11021454 44 27 HGNC:12805 Type of aryl benzofuran amidated derivative and medical use thereof CHINA PHARMACEUTICAL UNIVERSITY 11/28/212D 3D TSV
US11014905 114 36 HGNC:3023 HGNC:5286 2,6-disubstituted pyridine derivative SUMITOMO DAINIPPON PHARMA CO., LTD. 11/22/212D 3D TSV
US11014923 152 37 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Bicyclic heterocycles as FGFR4 inhibitors Incyte Corporation 11/22/212D 3D TSV
US11014911 1035 569 HGNC:1780 HGNC:1771 HGNC:4617 HGNC:1777 HGNC:1722 HGNC:1773 CDK2 inhibitors Pfizer Inc. 11/22/212D 3D TSV
US11014912 68 68 Cyanopyrrolidine derivatives with activity as inhibitors of USP30 MISSION THERAPEUTICS LIMITED 11/22/212D 3D TSV
US11014920 36 35 HGNC:3530 Factor XIIa inhibitors Merck Sharp & Dohme Corp. 11/22/212D 3D TSV
US11014930 78 78 HGNC:9967 Fused pyrimidine compound or salt thereof Taiho Pharmaceutical Co., Ltd. 11/22/212D 3D TSV
US11014909 81 72 HGNC:3020 Heteroaromatic compounds and their use as dopamine D1 ligands Pfizer Inc. 11/22/212D 3D TSV
US11013718 9 9 HGNC:29079 LSD1 inhibitors and medical uses thereof Constellation Pharmaceuticals, Inc. 11/22/212D 3D TSV
US11014929 126 126 HGNC:6863 Pyrazolopyrimidine compounds and uses thereof Incyte Corporation 11/22/212D 3D TSV
US11014913 855 800 Pyridazinones as PARP7 inhibitors Ribon Therapeutics, Inc. 11/22/212D 3D TSV
US11014926 35 30 HGNC:7110 HGNC:7111 Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit MNK1 and MNK2 eFFECTOR Therapeutics, Inc. 11/22/212D 3D TSV
US11013745 80 79 Triazolopyrimidine, triazolopyridine compounds, and the composition thereof for treating PRC2-mediated diseases SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES; SUZHOU SUPLEAD LIFE SCIENCES CO., LTD. 11/22/212D 3D TSV
US11014963 205 202 Trifluoromethylpropanamide derivatives as HTRA1 inhibitors Hoffmann-La Roche Inc. 11/22/212D 3D TSV
US11008338 48 25 HGNC:934 HGNC:933 C5-C6-oxacyclic fused iminothiazine dioxide compounds bearing an ether linker as BACE inhibitors, compositions, and their use Merck Sharp & Dohme Corp. 11/15/212D 3D TSV
US11008314 623 155 HGNC:1133 HGNC:6193 HGNC:6171 HGNC:12434 Compounds and methods for modulating interleukin-2-inducible t-cell kinase Corvus Pharmaceuticals, Inc. 11/15/212D 3D TSV
US11008336 22 8 HGNC:10259 HGNC:10258 Compounds useful for inhibiting RORγt Eli Lilly and Company 11/15/212D 3D TSV
US11007200 16 8 HGNC:8157 Cycloalkyl-diamines for the treatment of pain MediSynergics, LLC 11/14/212D 3D TSV
US11008301 42 21 HGNC:3827 HGNC:3826 Piperidinone formyl peptide 2 receptor agonists Bristol-Myers Squibb Company 11/14/212D 3D TSV
US11008312 373 359 Pyridazine derivatives as RORc modulators Genentech, Inc. 11/14/212D 3D TSV
US11008308 435 420 HGNC:29232 Quinazolinones as PARP14 inhibitors Ribon Therapeutics Inc. 11/14/212D 3D TSV
US11008304 85 85 HGNC:6857 Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof Enanta Pharmaceuticals, Inc. 11/14/212D 3D TSV
US11000525 30 15 HGNC:7218 HGNC:12015 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase ASTRAZENECA AB 11/08/212D 3D TSV
US11001596 70 8 HGNC:5383 HGNC:5382 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors Eli Lilly and Company 11/08/212D 3D TSV
US11001586 178 88 HGNC:7027 HGNC:12446 Alkyl pyrrolopyrimidine analogs and methods of making and using same The University of North Carolina at Chapel Hill 11/08/212D 3D TSV
USRE48547 6 6 HGNC:6027 Aminopyrimidinecarboxamides as CXCR2 modulators Syntrix Biosystems Inc. 11/08/212D 3D TSV
US11001575 923 899 HGNC:6871 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. 11/08/212D 3D TSV
US11000528 26 11 Compound useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV 11/08/212D 3D TSV
US10995099 93 59 HGNC:85 HGNC:84 Compounds and their uses as ACC inhibitors Nanjing Ruijie Pharmatech Co., Ltd. 11/08/212D 3D TSV
US11000515 25 25 Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease Shy Therapeutics LLC 11/08/212D 3D TSV
US11001555 22 22 Difluoroketamide derivatives as HTRA1 inhibitors Hoffman-La Roche Inc. 11/08/212D 3D TSV
US11001583 16 16 Dihydropyrrolopyridine inhibitors of ROR-gamma Vitae Pharmaceuticals, LLC 11/08/212D 3D TSV
US11001600 13 13 HGNC:2771 Disubstituted compounds for treatment of medical disorders Achillion Pharmaceuticals, Inc. 11/08/212D 3D TSV
US11001568 170 44 HGNC:29012 HGNC:17071 HGNC:18039 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. 11/08/212D 3D TSV
US11001578 188 92 HGNC:6371 HGNC:6357 N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors KALVISTA PHARMACEUTICALS LIMITED 11/08/212D 3D TSV
US11001589 51 51 HGNC:3650 Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors ASTRAZENECA AB 11/08/212D 3D TSV
US11001595 32 13 HGNC:3763 HGNC:2861 HGNC:6307 HGNC:8804 HGNC:3236 Pyrimidine compounds and pyrimido indole compounds and methods of use Duquesne University of The Holy Spirit 11/08/212D 3D TSV
US11001572 40 10 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Pyrimidine derivative, method for preparing same and use thereof in medicine TBA 11/08/212D 3D TSV
US11001561 146 136 HGNC:9644 Pyrimidinone derivatives as SHP2 antagonists Merck Patent GmbH 11/08/212D 3D TSV
US11001563 81 81 HGNC:550 SSAO inhibitor TBA 11/08/212D 3D TSV
US10995070 15 15 HGNC:84 Acetyl-CoA carboxylase modulators Monsanto Technology LLC 11/04/212D 3D TSV
US10994015 521 108 HGNC:3430 HGNC:3431 HGNC:3236 EGFR proteolysis targeting chimeric molecules and associated methods of use ARVINAS OPERATIONS, INC.; YALE UNIVERSITY 11/04/212D 3D TSV
US10995072 124 57 HGNC:3538 Inhibitors of protease-activated receptor-2 Heptares Therapeutics Limited 11/04/212D 3D TSV
US10995088 309 162 HGNC:6833 HGNC:6834 HGNC:2671 HGNC:6664 HGNC:6666 Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL 11/04/212D 3D TSV
US10995073 253 218 HGNC:8605 HGNC:270 PARG inhibitory compounds Cancer Research Technology Limited 11/04/212D 3D TSV
US10995084 192 116 HGNC:16709 Pyrrolidine derivative KISSEI PHARMACEUTICAL CO., LTD. 11/04/212D 3D TSV
US10995090 21 19 HGNC:7056 Substituted dihydrobenzofuran glycosidase inhibitors Asceneuron SA 11/04/212D 3D TSV
US10995089 92 92 HGNC:6871 Zaindole derivatives and their use as ERK kinase inhibitors AGV DISCOVERY; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS); UNIVERSITE DE MONTPELLIER 11/04/212D 3D TSV
US10988455 108 53 HGNC:262 HGNC:263 1,2,4-triazine-4-amine derivatives Heptares Therapeutics Limited 11/01/212D 3D TSV
US10988502 64 32 HGNC:6561 HGNC:6563 Alpha-D-galactoside inhibitors of galectins GALECTO BIOTECH AB 11/01/212D 3D TSV
US10988458 71 70 HGNC:6857 Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof Enanta Pharmaceuticals, Inc. 11/01/212D 3D TSV
US10988459 91 77 Bicyclic lactams and methods of use thereof Genentech, Inc. 11/01/212D 3D TSV
US10988445 310 136 Compounds AstraZeneca AB 11/01/212D 3D TSV
US10988482 108 99 HGNC:17967 IRAK4 inhibitor and use thereof BEIJING HANMI PHARMACEUTICAL CO., LTD. 11/01/212D 3D TSV
US10988507 2 2 Immunomodulators bristol-myers squibb company 11/01/212D 3D TSV
US10987354 24 23 Inhibitors of influenza virus replication and uses thereof SUNSHINE LAKE PHARMA CO., LTD. 11/01/212D 3D TSV
US10988451 457 440 MCL-1 inhibitors Gilead Sciences, Inc. 11/01/212D 3D TSV
US10988481 66 20 HGNC:8153 HGNC:8154 HGNC:8156 Potent and selective mu opioid receptor modulators Virginia Commonwealth University 11/01/212D 3D TSV
US10988462 37 37 HGNC:11036 Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof Japan Tobacco Inc. 11/01/212D 3D TSV
US10988478 551 532 HGNC:17967 Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators Genentech, Inc. 11/01/212D 3D TSV
US10988463 79 55 Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors Pfizer Inc. 11/01/212D 3D TSV
US10988487 242 204 HGNC:6059 Substituted n′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors Merck Sharp & Dohme Corp. 11/01/212D 3D TSV
US10988476 635 140 HGNC:1780 HGNC:1771 HGNC:1778 HGNC:1722 HGNC:1777 HGNC:1774 HGNC:1773 Substituted pyrimidines as cyclin-dependent kinase inhibitors SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. 11/01/212D 3D TSV
US10981917 230 229 HGNC:9462 Heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same Daewoong Pharmaceutical Co., Ltd. 10/27/212D 3D TSV
US10981916 25 25 Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors DART NEUROSCIENCE, LLC 10/27/212D 3D TSV
US10981926 3 1 HGNC:7978 HGNC:644 Substituted thiohydantoin derivatives as androgen receptor antagonists Janssen Pharmaceutica NV 10/27/212D 3D TSV
US10981914 16 11 HGNC:15631 HGNC:6018 Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor Bristol-Myers Squibb Companay 10/27/212D 3D TSV
US10981904 67 61 1,3,4-thiadiazole compounds and their use in treating cancer Cancer Research Technology Limited 10/26/212D 3D TSV
US10980781 21 18 HGNC:12630 6-amino-2,4-dihydropyrano [2,3-c] pyrazoles and methods of use Purdue Research Foundation 10/26/212D 3D TSV
US10980815 468 113 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Aminopyrimidinyl compounds Pfizer Inc. 10/26/212D 3D TSV
US10981887 50 25 HGNC:3467 Benzothiophene estrogen receptor modulators G1 Therapeutics, Inc. 10/26/212D 3D TSV
US10981910 237 236 HGNC:19679 Biaryl kinase inhibitors Bristol-Myers Squibb Company 10/26/212D 3D TSV
US10981882 19 19 HGNC:6059 Compound for inhibiting IDO, a manufacturing method and a use thereof Shanghai JOYU Pharmatech Ltd. 10/26/212D 3D TSV
US10981881 16 8 HGNC:7967 FXR (NR1H4) modulating compounds Gilead Sciences, Inc. 10/26/212D 3D TSV
US10981905 154 49 HGNC:10593 HGNC:10585 HGNC:10596 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents Xenon Pharmaceuticals Inc. 10/26/212D 3D TSV
US10981911 840 210 Imidazopyrrolopyridine as inhibitors of the JAK family of kinases Janssen Pharmaceutica NV 10/26/212D 3D TSV
US10981896 43 22 HGNC:16870 HGNC:1925 HGNC:1470 HGNC:9377 HGNC:14311 HGNC:6871 Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 10/26/212D 3D TSV
US10981899 9 5 HGNC:21285 Inhibitors of soluble adenylyl cyclase Cornell University; Tri-Institutional Therapeutics Discovery Institute 10/26/212D 3D TSV
US10981898 89 85 Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity ASTEX THERAPEUTICS LIMITED; CANCER RESEARCH TECHNOLOGY LIMITED 10/26/212D 3D TSV
US10980794 334 329 PRMT5 inhibitors and uses thereof Epizyme, Inc. 10/26/212D 3D TSV
US10981906 110 51 HGNC:6190 Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same ACLARIS THERAPEUTICS, INC. 10/26/212D 3D TSV
US10981893 35 30 HGNC:6371 Therapeutic inhibitory compounds ATTUNE PHARMACEUTICALS, INC. 10/26/212D 3D TSV
US10981879 189 164 HGNC:7218 Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase Bristol-Myers Squibb Company 10/26/212D 3D TSV
US10980809 132 95 HGNC:6307 HGNC:9829 HGNC:1097 Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED 10/26/212D 3D TSV
US10975062 135 135 4-aminoquinazolinyl compounds as prolyl hydroxylase inhibitors TBA 10/20/212D 3D TSV
US10975057 94 92 6-aminopyridin-3-yl pyrazoles as modulators of RORgT Janssen Pharmaceutica NV 10/20/212D 3D TSV
US10975068 453 440 6-aminopyridin-3-yl thiazoles as modulators of RORγT Janssen Pharmaceutica NV 10/20/212D 3D TSV
US10975066 25 25 HGNC:11138 Bis-heteroaryl derivatives as modulators of protein aggregation UCB Biopharma SRL 10/20/212D 3D TSV
US10975080 72 71 HGNC:9644 Compounds and compositions for inhibiting the activity of SHP2 NOVARTIS AG 10/20/212D 3D TSV
US10975030 28 28 HGNC:5253 Grp94 selective inhibitors and uses thereof University of Kansas; University of South Florida 10/20/212D 3D TSV
US10975075 471 134 HGNC:8978 HGNC:795 HGNC:8975 HGNC:3942 HGNC:8977 HGNC:8976 Imidazolonylquinolines and the use thereof as ATM kinase inhibitors Merck Patent GmbH 10/20/212D 3D TSV
US10975058 8 4 HGNC:4840 HGNC:1133 Imidazolyl kinase inhibitors and uses thereof Dana-Farber Cancer Institute, Inc. 10/20/212D 3D TSV
US10975084 185 185 HGNC:18039 KDM5 inhibitors Merck Sharp & Dohme Corp. 10/20/212D 3D TSV
US10975049 22 22 Nicotinyl alcohol ether derivative, preparation method therefor, and pharmaceutical composition and uses thereof Institute of Materia Medica, Chinese Academy of Medical Sciences; Tianjin Chase Sun Pharmaceutical Co., LTD 10/20/212D 3D TSV
US10973817 147 146 HGNC:1925 Pharmaceutical compounds SENTINEL ONCOLOGY LIMITED 10/20/212D 3D TSV
US10975037 228 225 Phenyl substituted pyrazoles as modulators of RORγt Janssen Pharmaceutica NV 10/20/212D 3D TSV
US10975091 290 150 HGNC:6656 Pyridine derivative Astellas Pharma Inc.; KOTOBUKI PHARMACEUTICAL CO., LTD. 10/20/212D 3D TSV
US10975064 27 27 RIP1 inhibitory compounds and methods for making and using the same Rigel Pharmaceuticals, Inc. 10/20/212D 3D TSV
US10975081 18 16 HGNC:18618 Substituted fused pyrazole compounds and their use as LRRK2 inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED 10/20/212D 3D TSV
US10975056 659 644 HGNC:2976 Substituted pyridines as inhibitors of DNMT1 GlaxoSmithKline Intellectual Property Development Limited; Cancer Research Technology Ltd. 10/20/212D 3D TSV
US10968216 332 297 HGNC:2867 4,5-annulated 1,2,4-triazolones BAYER AKTIENGESELLSCHAFT; BAYER PHARMA AKTIENGESELLSCHAFT; THE BROAD INSTITUTE, INC.; PRESIDENT AND FELLOWS OF HARVARD COLLEGE; THE GENERAL HOSPITAL CORPORATION 10/09/212D 3D TSV
US10968163 97 34 HGNC:3560 HGNC:3557 Alpha-truxillic acid derivatives and pharmaceutical compositions thereof The Research Foundation for the State University of New York 10/09/212D 3D TSV
US10968188 153 114 HGNC:8803 HGNC:76 HGNC:6342 Benzothiazol compounds and methods using the same for treating neurodegenerative disorders 1st Biotherapeutics, Inc. 10/09/212D 3D TSV
US10968198 35 35 HGNC:7097 Biaryltriazole inhibitors of macrophage migration inhibitory factor Yale University 10/09/212D 3D TSV
US10968199 30 29 HGNC:6857 Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof Enanta Pharmaceuticals, Inc. 10/09/212D 3D TSV
US10968242 106 35 Cyclopentane-based modulators of STING (stimulator of interferon genes) Pfizer Inc. 10/09/212D 3D TSV
US10968213 375 107 HGNC:6833 HGNC:6834 HGNC:29079 Cyclopropanamine compound and use thereof Takeda Pharmaceutical Company Limited 10/09/212D 3D TSV
US10968223 155 155 HGNC:550 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors Proximagen, LLC 10/09/212D 3D TSV
US10968227 45 45 HGNC:4596 Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction Vanderbilt University 10/09/212D 3D TSV
US10966985 52 13 HGNC:10261 Macrocyclic compounds as ROS1 kinase inhibitors Array BioPharma Inc. 10/09/212D 3D TSV
US10968215 227 189 HGNC:3527 Pyrido five-element aromatic ring compound, preparation method therefor and use thereof SHANGHAI HAIHE PHARMACEUTICAL CO., LTD.; SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES 10/09/212D 3D TSV
US10966980 1100 273 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Pyrrolo[2,3-d]pyrimidine derivatives Pfizer Inc. 10/09/212D 3D TSV
US10968221 13 13 HGNC:29079 Substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors Incyte Corporation 10/09/212D 3D TSV
US10967060 22 22 HGNC:6059 Synergistic combination of immunologic inhibitors for the treatment of cancer The University of Chicago 10/09/212D 3D TSV
US10968236 184 91 HGNC:6192 HGNC:12440 TYK2 inhibitors and uses thereof Nimbus Lakshmi, Inc. 10/09/212D 3D TSV
US10966987 23 23 HGNC:6307 Therapeutic compounds and uses thereof Kala Pharmaceuticals, Inc. 10/09/212D 3D TSV
US10968172 90 90 USP30 inhibitors Mitobridge, Inc. 10/09/212D 3D TSV
US10961236 249 63 HGNC:8975 HGNC:8977 HGNC:8976 (S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino) thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one as a phosphatidylinositol 3-kinase inhibitor AstraZeneca AB 10/04/212D 3D TSV
US10961241 73 66 Chemical compounds AstraZeneca AB 10/04/212D 3D TSV
US10961242 81 80 HGNC:3357 Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same LegoChem Biosciences, Inc. 10/04/212D 3D TSV
US10961198 66 66 HGNC:7967 Farnesoid X receptor agonists and uses thereof METACRINE, INC. 10/04/212D 3D TSV
US10961237 146 145 HGNC:1133 Inhibiting agents for Bruton's tyrosine kinase BIOGEN MA INC. 10/04/212D 3D TSV
US10961228 198 66 JAK1 selective inhibitors ASTRAZENECA AB 10/04/212D 3D TSV
US10961249 21 21 Modulators of the sigma-2 receptor and their method of use TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 10/04/212D 3D TSV
US10961233 46 45 Oxazole derivatives for use in the treatment of cancer LIFEARC 10/04/212D 3D TSV
US10961256 3 3 HGNC:10894 PRMT5 inhibitors CTXT PTY LTD 10/04/212D 3D TSV
US10961247 365 180 HGNC:1133 HGNC:6193 Pyrazolopyrimidine derivatives as kinase inhibitor Daewoong Pharmaceutical Co., Ltd. 10/04/212D 3D TSV
US10961252 34 34 HGNC:1037 Quinazoline and indole compounds to treat medical disorders Achillion Pharmaceuticals, Inc. 10/04/212D 3D TSV
US10961200 522 512 HGNC:6535 Small molecule inhibitors of lactate dehydrogenase and methods of use thereof THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; VANDERBILT UNIVERSITY; THE UAB RESEARCH FOUNDATION; THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 10/04/212D 3D TSV
US10961232 603 568 HGNC:882 Substituted pyrazines as ATR kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED 10/04/212D 3D TSV
US10960005 122 119 HGNC:29079 Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas CELGENE QUANTICEL RESEARCH, INC. 10/04/212D 3D TSV
US10954228 149 145 HGNC:6535 1 H-pyrazol-1-yl-thiazoles as inhibitors of lactate dehydrogenase and methods of use thereof THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA; THE UAB RESEARCH FOUNDATION; VANDERBILT UNIVERSITY; NATIONAL INSTITUTES OF HEALTH, UNITED STATES DEPT. OF HEALTH AND HUMAN SERVICES 09/28/212D 3D TSV
US10954253 76 75 HGNC:12761 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one derivative as Wee1 inhibitor SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT CO., LTD. 09/28/212D 3D TSV
US10952995 27 27 HGNC:6863 Azaindoles as inhibitors of HPK1 Genentech, Inc. 09/28/212D 3D TSV
US10954216 119 90 HGNC:171 BMP-signal-inhibiting compound RIKEN; THE UNIVERSITY OF TOKYO 09/28/212D 3D TSV
US10954244 11 11 HGNC:6307 Compounds and uses thereof Kala Pharmaceuticals, Inc. 09/28/212D 3D TSV
US10954240 60 60 Compounds inhibiting leucine-rich repeat kinase enzyme activity Merck Sharp & Dohme Corp. 09/28/212D 3D TSV
US10954241 320 108 HGNC:6307 HGNC:9967 Heterocyclic compounds as ret kinase inhibitors Cancer Research Technology Limited 09/28/212D 3D TSV
US10953012 420 239 HGNC:2459 Heterocyclic compounds for the inhibition of pask BioEnergenix LLC 09/28/212D 3D TSV
US10954237 56 19 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 JAK inhibitors containing a 4-membered heterocyclic amide Theravance Biopharma R&D IP, LLC 09/28/212D 3D TSV
US10947254 1048 261 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Methods for treating ulcerative colitis using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile Theravance Biopharma R&D IP, LLC 09/28/212D 3D TSV
US10952992 100 97 HGNC:9665 Methods of treating intraocular pressure with activators of Tie-2 AERPIO PHARMACEUTICALS, INC. 09/28/212D 3D TSV
US10954214 449 444 HGNC:6819 Pyrazole derivatives as MALT1 inhibitors Janssen Pharmaceutica NV 09/28/212D 3D TSV
US10954225 28 15 Selective NR2B antagonists Bristol-Myers Squibb Company 09/28/212D 3D TSV
US10954217 86 43 HGNC:8157 Sigma receptor binders BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 09/28/212D 3D TSV
US10954243 22 22 Substituted heterocyclic inhibitors of PTPN11 NAVIRE PHARMA, INC. 09/28/212D 3D TSV
US10954193 147 134 HGNC:6943 HGNC:992 HGNC:990 Substituted indole Mcl-1 inhibitors Vanderbilt University 09/28/212D 3D TSV
US10953005 1229 556 HGNC:9967 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors Array Biopharma Inc. 09/28/212D 3D TSV
US10947203 176 88 HGNC:7968 1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane X receptor ST. JUDE CHILDREN''S RSEARCH HOSPITAL 09/26/212D 3D TSV
US10947218 616 87 Aminopyridine derivatives and their use as selective ALK-2 inhibitors NOVARTIS AG 09/26/212D 3D TSV
US10947196 8 4 HGNC:285 HGNC:286 Beta adrenergic agonist and methods of using the same CuraSen Therapeutics, Inc. 09/26/212D 3D TSV
US10947230 162 54 HGNC:3690 HGNC:3689 HGNC:3688 Bicyclic heterocycles as FGFR inhibitors Incyte Corporation; Incyte Holdings Corporation 09/26/212D 3D TSV
US10947226 23 23 Bicyclic pyridone lactams and methods of use thereof Genentech, Inc. 09/26/212D 3D TSV
US10945994 17 3 HGNC:11708 HGNC:6059 Combinations comprising a pyrrolidine-2,5-dione IDO1 inhibitor and an anti-body Pfizer Inc.; iTEOS THERAPEUTICS 09/26/212D 3D TSV
US10947229 48 12 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Dimethyl amino azetidine amides as JAK inhibitors Theravance Biopharma R&D IP, LLC 09/26/212D 3D TSV
US10947243 391 79 HGNC:11390 HGNC:4617 HGNC:3765 Heteroaryl SYK inhibitors Boehringer Ingelheim International GmbH 09/26/212D 3D TSV
US10947215 458 449 Heteroaryl compounds and their use as therapeutic drugs Dong-A Socio Holdings Co., Ltd. 09/26/212D 3D TSV
US10947222 72 72 HGNC:16940 Indole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 Merck Sharp & Dohme Corp. 09/26/212D 3D TSV
US10947210 164 135 Inhibitors of Hepatitis C virus polymerase COCRYSTAL PHARMA, INC. 09/26/212D 3D TSV
US10947252 558 547 Inhibitors of KEAP1-Nrf2 protein-protein interaction Janssen Pharmaceutica NV 09/26/212D 3D TSV
US10946019 33 33 HGNC:10477 Nurr1:RXR activating compounds for simultaneous treatment of symptoms and pathology of Parkinson's disease TBA 09/26/212D 3D TSV
US10947234 36 12 HGNC:10894 PRMT5 inhibitors Merck Sharp & Dohme Corp. 09/26/212D 3D TSV
US10947241 26 26 Phenyl phthalazine derivative, method for the preparation thereof, and pharmaceutical composition comprising the same Seoul National University Hospital 09/26/212D 3D TSV
US10947223 72 18 HGNC:2529 HGNC:933 Substituted oxazines as beta-secretase inhibitors Amgen Inc. 09/26/212D 3D TSV
US10946017 22 11 HGNC:11584 Tank-binding kinase-1 PROTACs and associated methods of use ARVINAS OPERATIONS, INC. 09/26/212D 3D TSV
US10947251 76 38 HGNC:10597 Therapeutic compounds and methods of use thereof GENENTECH, INC. 09/26/212D 3D TSV
US10946023 1073 391 Therapeutically active compounds and their methods of use Agios Pharmaceuticals, Inc. 09/26/212D 3D TSV
US10945978 12 6 HGNC:7966 HGNC:7965 Treatment and diagnosis of melanoma The Rockefeller University 09/26/212D 3D TSV
US10947239 8 1 HGNC:8778 [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound Janssen Pharmaceutica NV 09/26/212D 3D TSV
US10941129 26 26 Benzyl phenyl ether derivative, preparation method therefor, and pharmaceutical composition and uses thereof Institute of Materia Medica, Chinese Academy of Medical Sciences; Tianjin Chase Sun Pharmaceutical Co., LTD 09/20/212D 3D TSV
US10941160 505 499 HGNC:13575 Bromodomain inhibitors Celgene Quanticel Research, Inc. 09/20/212D 3D TSV
US10941151 50 29 HGNC:11526 HGNC:11527 HGNC:11528 Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof Ogeda SA 09/20/212D 3D TSV
US10940139 25 25 Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease Shy Therapeutics LLC 09/20/212D 3D TSV
US10941162 32 8 HGNC:8978 HGNC:8980 HGNC:8975 HGNC:8977 Heterocyclic compounds and uses thereof Infinity Pharmaceuticals, Inc. 09/20/212D 3D TSV
US10941115 196 72 HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6524 HGNC:6876 Kinase inhibitors Oxular Acquisitions Limited 09/20/212D 3D TSV
US10941146 31 31 Methods for inhibiting fascin NOVITA PHARMACEUTICALS, INC.; CORNELL UNIVERSITY 09/20/212D 3D TSV
US10941138 193 88 HGNC:1399 Quinoline and isoquinoline derivatives for treating pain and pain related conditions ESTEVE PHARMACEUTICALS, S.A. 09/20/212D 3D TSV
US10934296 665 131 HGNC:6735 HGNC:4037 HGNC:1133 HGNC:11283 HGNC:6524 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors Merck Sharp & Dohme B.V. 09/12/212D 3D TSV
US10934297 286 143 HGNC:4617 HGNC:3091 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof Samumed, LLC 09/12/212D 3D TSV
US10934303 124 28 HGNC:3474 HGNC:3473 HGNC:3471 HGNC:3467 Aryl ethene derivative and pharmaceutical composition containing same as active ingredient DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION; KYUNGPOOK NATIONAL UNIVERSITY HOSPITAL; KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION 09/12/212D 3D TSV
US10933063 258 214 HGNC:6735 HGNC:1133 HGNC:6171 HGNC:11719 HGNC:3236 HGNC:6524 Bruton's tyrosine kinase inhibitors Suzhou Baijibugong Pharmaceutical Technology Co., Ltd. 09/12/212D 3D TSV
US10934285 61 61 Compounds and compositions for inhibiting the activity of SHP2 NOVARTIS AG 09/12/212D 3D TSV
US10934310 484 472 HGNC:1133 Inhibitors of Bruton's tyrosine kinase and method of their use Janssen Pharmaceutica NV 09/12/212D 3D TSV
US10934288 241 236 HGNC:6863 Pyrazolopyridine compounds and uses thereof Incyte Corporation 09/12/212D 3D TSV
US10934305 54 32 HGNC:10852 HGNC:10850 SHMT inhibitors The Trustees of Princeton University 09/12/212D 3D TSV
US10934302 294 288 SHP2 phosphatase inhibitors and methods of use thereof Relay Therapeutics, Inc. 09/12/212D 3D TSV
US10934304 88 87 HGNC:6871 Spirocyclic compounds Recurium IP Holdings, LLC 09/12/212D 3D TSV
US10934294 124 60 Substituted pyrazolo[3,4-d]pyrimidines as PDE9 inhibitors Merck Sharp & Dohme Corp. 09/12/212D 3D TSV
US10927106 45 44 HGNC:3091 Benzothiazole derivatives as DYRK1 inhibitors PHARMASUM THERAPEUTICS AS 09/06/212D 3D TSV
US10927120 50 45 HGNC:1771 HGNC:1773 CDK inhibitors GI Therapeutics, Inc. 09/06/212D 3D TSV
US10927110 31 31 Cyano-subtituted heterocycles with activity as inhibitors of USP30 MISSION THERAPEUTICS LIMITED 09/06/212D 3D TSV
US10927076 96 48 HGNC:5258 HGNC:5253 HSP90B N-terminal isoform-selective inhibitors University of Kansas 09/06/212D 3D TSV
US10927111 79 62 HGNC:9829 Inhibitors of RAF kinases KINNATE BIOPHARMA INC. 09/06/212D 3D TSV
US10927079 74 69 HGNC:8031 Intermediate compound of novel tetrahydronaphthyl urea derivative MOCHIDA PHARMACEUTICAL CO., LTD. 09/06/212D 3D TSV
US10927123 36 35 HGNC:288 Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto Arena Pharmaceuticals, Inc. 09/06/212D 3D TSV
US10927128 113 112 HGNC:575 Oxadiazaspiro compounds for the treatment of drug abuse and addiction ESTEVE PHARMACEUTICALS. S.A. 09/06/212D 3D TSV
US10927105 323 248 HGNC:17038 Pyrazole MAGL inhibitors LUNDBECK LA JOLLA RESEARCH CENTER, INC. 09/06/212D 3D TSV
US10927086 86 48 HGNC:6059 Substituted sulfoximine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors Merck Sharp & Dohme Corp. 09/06/212D 3D TSV
US10925881 14 7 Treatment of conditions associated with hyperinsulinaemia Tensha Therapeutics, Inc. 09/06/212D 3D TSV
US10925840 52 26 HGNC:285 HGNC:286 Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas The USA, as represented by the Secretary, Department of Health and Human Services; SRI International 09/06/212D 3D TSV
US10919884 8 8 HGNC:2771 Amide compounds for treatment of immune and inflammatory disorders Achillion Pharmaceuticals, Inc. 09/02/212D 3D TSV
US10918640 19 18 HGNC:3553 Azetidine derivatives Vernalis (R&D) Ltd. 09/02/212D 3D TSV
US10919859 57 56 HGNC:4498 Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof Boehringer Ingelheim International GmbH 09/02/212D 3D TSV
US10919843 18 9 HGNC:4910 Cannabidiol derivatives as inhibitors of the HIF prolyl hydroxylases activity Emerald Health Pharmaceuticals Inc. 09/02/212D 3D TSV
US10919885 926 463 HGNC:10571 HGNC:21088 Compounds and uses thereof Yumanity Therapeutics, Inc. 09/02/212D 3D TSV
US10919856 36 18 Cyclohexene compounds and use thereof GUANGZHOU HENOVCOM BIOSCIENCE CO. LTD. 09/02/212D 3D TSV
US10919862 9 6 Fused imidazoles as mIDH1 inhibitors BAYER PHARMA AKTIENGESELLSCHAFT 09/02/212D 3D TSV
US10919902 46 23 HGNC:4852 HGNC:4853 Hetero-halo inhibitors of histone deacetylase Alkermes, Inc. 09/02/212D 3D TSV
US10919914 6 3 HGNC:8978 HGNC:8977 Heterocyclic compounds and uses thereof Infinity Pharmaceuticals, Inc. 09/02/212D 3D TSV
US10919901 5 5 HGNC:7029 Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors Incyte Holdings Corporation; Incyte Corporation 09/02/212D 3D TSV
US10919899 20 12 HGNC:1133 HGNC:6171 HGNC:11719 HGNC:12434 Imidazopyrazine compounds, preparation methods and uses thereof DONGGUAN ZHENXING-BEITE MEDICINE TECHNOLOGY CO., LTD. 09/02/212D 3D TSV
US10919852 416 407 Immunomodulator compounds ChemoCentryx, Inc. 09/02/212D 3D TSV
US10918642 68 68 HGNC:3255 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors Nerviano Medical Sciences S.R.L. 09/02/212D 3D TSV
US10919890 4 1 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders GALAPAGOS NV 09/02/212D 3D TSV
US10919913 67 56 HGNC:6973 Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors Boehringer Ingelheim International GmbH 09/02/212D 3D TSV
US10918645 91 51 HGNC:6192 Substituted tricyclic heterocyclic compounds and use thereof LIFEARC; SUZHOU YABAO PHARMACEUTICAL R&D CO., LTD. 09/02/212D 3D TSV
US10919869 50 49 HGNC:2867 Thiazole derivative and applications EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY 09/02/212D 3D TSV
US10919858 71 70 HGNC:17989 Thioacetate compounds, compositions and methods of use Ardea Biosciences, Inc 09/02/212D 3D TSV
US10919895 66 37 HGNC:15631 HGNC:6018 Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor Bristol-Myers Squibb Company 09/02/212D 3D TSV
US10919911 81 80 HGNC:6857 Tricyclic ASK1 inhibitors TERNS, INC. 09/02/212D 3D TSV
US10913710 100 99 HGNC:8788 Benzene disulfonamide for the treatment of cancer Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V 08/30/212D 3D TSV
US10913735 14 14 HGNC:11138 Bis-heteroaryl derivatives as modulators of protein aggregation UCB Biopharma SRL 08/30/212D 3D TSV
US10912773 302 107 HGNC:8775 HGNC:8774 HGNC:8776 Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors H. Lundbeck A/S 08/30/212D 3D TSV
US10913740 112 16 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 JAK kinase inhibitor compounds for treatment of respiratory disease Theravance Biopharma R&D IP, LLC 08/30/212D 3D TSV
US10913744 54 20 LRRK2 inhibitors and methods of making and using the same DANA-FARBER CANCER INSTITUTE, INC. 08/30/212D 3D TSV
US10913745 49 47 HGNC:10548 Octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors Hoffmann-La Roche Inc. 08/30/212D 3D TSV
US10913742 110 110 HGNC:497 Oxadiazolones as transient receptor potential channel inhibitors Genentech, Inc. 08/30/212D 3D TSV
US10913711 189 59 Potent and selective inhibitors of monoamine transporters; method of making; and use thereof THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 08/30/212D 3D TSV
US10912774 144 67 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Pyrimidine FGFR4 inhibitors EISAI R&D MANAGEMENT CO., LTD. 08/30/212D 3D TSV
US10913746 124 111 HGNC:9922 Substituted 4-phenylpiperidines, their preparation and use The Trustees of Columbia University in the City of New York 08/30/212D 3D TSV
US10913733 54 50 HGNC:7056 Substituted piperidines thiazolyl acetamides as glycosidase inhibitors and uses thereof Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp. 08/30/212D 3D TSV
US10913753 410 219 Thienopyridine carboxamides as ubiquitin-specific protease inhibitors VALO EARLY DISCOVERY, INC. 08/30/212D 3D TSV
US10905688 302 111 HGNC:8775 HGNC:8774 HGNC:8776 Combinations comprising substituted imidazo[1,5-α]pyrazinones as PDE1 inhibitors H. Lundbeck A/S 08/22/212D 3D TSV
US10906896 132 42 HGNC:77 HGNC:76 HGNC:6342 Compositions and methods for inhibiting kinases Inhibikase Therapeutics, Inc. 08/22/212D 3D TSV
US10906900 62 14 HGNC:11138 Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE D''ORLEANS; UNIVERSITE DE TOURS; CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) 08/22/212D 3D TSV
US10906905 88 52 HGNC:6307 HGNC:6876 Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof Jiangsu Hengrui Medicine Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd. 08/22/212D 3D TSV
US10906920 68 65 Heterocyclic compounds as immunomodulators Incyte Corporation 08/22/212D 3D TSV
US10906878 7 7 HGNC:1133 Kinase inhibitors for the treatment of disease DANA FARBER CANCER INSTITUTE, INC. 08/22/212D 3D TSV
US10906888 205 198 Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme Pfizer Inc. 08/22/212D 3D TSV
US10905687 20 20 Substituted piperazines as ROR-gamma modulators ESCALIER BIOSCIENCES B.V. 08/22/212D 3D TSV
US10906915 372 370 HGNC:8783 Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors LEO Pharma A/S 08/22/212D 3D TSV
US10906890 112 103 HGNC:339 Triazole phenyl compounds as agonists of the APJ receptor AMGEN INC. 08/22/212D 3D TSV
US10899772 34 34 HGNC:17967 IRAK4 modulators Genentech, Inc. 08/16/212D 3D TSV
US10899774 71 71 HGNC:17967 IRAK4 modulators Genentech, Inc. 08/16/212D 3D TSV
US10899741 9 4 HGNC:6307 HGNC:10020 HGNC:6876 3,4-bipyridyl pyrazole derivative, and preparation method therefor and medical application thereof Jiangsu Hengrui Medicine Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd. 08/15/212D 3D TSV
US10899755 32 32 HGNC:6863 Benzothiazole compounds and uses thereof Incyte Corporation 08/15/212D 3D TSV
US10899764 56 33 HGNC:11708 HGNC:6059 Imidazo isoindole derivative, preparation method therefor and medical use thereof JIANGSU HENGRUI MEDICINE CO., LTD.; SHANGHAI HENGRUI PHRMACEUTICAL CO., LTD. 08/15/212D 3D TSV
US10899769 268 124 Imidazopiperazinone inhibitors of transcription activating proteins Board of Regents, The University of Texas System 08/15/212D 3D TSV
US10899753 110 110 HGNC:1133 Inhibiting agents for Bruton's tyrosine kinase BIOGEN MA INC. 08/15/212D 3D TSV
US10899735 432 427 PD-1/PD-L1 inhibitors Gilead Sciences, Inc. 08/15/212D 3D TSV
US10899756 28 23 HGNC:8784 HGNC:8785 Phosphodiesterase inhibitors and uses thereof The Trustees of Columbia University in the City of New York 08/15/212D 3D TSV
US10899738 386 378 HGNC:7010 Piperidines as menin inhibitors THE REGENTS OF THE UNIVERSITY OF MICHIGAN 08/15/212D 3D TSV
US10898481 73 38 HGNC:262 HGNC:263 HGNC:264 Pyrazine compounds and uses thereof TBA 08/15/212D 3D TSV
US10894048 73 49 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Antitumor drug for intermittent administration of FGFR inhibitor Taiho Pharmaceutical Co., Ltd. 08/14/212D 3D TSV
US10894797 52 51 HGNC:9644 Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors Nikang Therapeutics, Inc. 08/14/212D 3D TSV
US10894789 334 165 HGNC:4849 HGNC:4848 Halo-substituted piperidines as orexin receptor modulators ASTRAZENECA AB; EOLAS THERAPEUTICS, INC. 08/14/212D 3D TSV
US10894784 652 648 HGNC:11584 Heteroarylbenzimidazole compounds BAYER PHARMA AKTIENGESELLSCHAFT 08/14/212D 3D TSV
US10894052 36 35 Heterocyclic inhibitors of ATR kinase Board of Regents, The University of Texas System; ChemPartner Corporation 08/14/212D 3D TSV
US10894038 20 19 HGNC:17989 Indolizine derivatives, composition and methods of use SHANGHAI FOCHON PHARMACEUTICAL CO. LTD.; FOCHON PHARMACEUTICALS, LTD. 08/14/212D 3D TSV
US10894788 199 161 Inhibitors of cyclin-dependent kinases KINNATE BIOPHARMA INC. 08/14/212D 3D TSV
US10894782 132 120 HGNC:12666 Modulators of P97 AAA ATPase activity University of Pittsburgh—Of the Commonwealth System of Higher Education 08/14/212D 3D TSV
US10894803 4 4 HGNC:5467 Multi-functionalized polysaccharide compounds and use thereof for targeting the cation-independent mannose 6-phosphate receptor NANOMEDSYN; Centre National de la Recherche Scientifique; Universite de Montpellier 08/14/212D 3D TSV
US10894807 103 102 HGNC:3788 PSMA imaging agents Siemens Medical Solutions USA, Inc. 08/14/212D 3D TSV
US10894794 3 3 HGNC:3009 Substituted [1,2,4]triazolo[4,3-a]pyrazines as antidiabetics King Abdulaziz University 08/14/212D 3D TSV
US10894786 141 46 HGNC:1778 HGNC:1733 Substituted pyrazole derivatives as selective CDK12/13 inhibitors Aurigene Discovery Technologies Limited 08/14/212D 3D TSV
US10889546 85 74 HGNC:1232 HGNC:14661 Alkynyl pyridine prolyl hydroxylase inhibitor, and preparation method and medical use thereof Jiangsu Hengrui Medicine Co., Ltd. 08/09/212D 3D TSV
US10889610 25 22 HGNC:6561 HGNC:6563 Alpha-D-galactoside inhibitors of galectins GALECTO BIOTECH AB 08/09/212D 3D TSV
US10889589 161 157 HGNC:8031 Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain Array BioPharma Inc. 08/09/212D 3D TSV
US10888561 14 14 HGNC:9843 CGRP receptor antagonists Heptares Therapeutics Limited 08/09/212D 3D TSV
US10889569 62 32 HGNC:897 HGNC:895 HGNC:896 Condensed ring group azacyclobutyl triazole derivative, preparation method therefor and use thereof in medicine Jiangsu Hengrui Medicine Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd. 08/09/212D 3D TSV
US10889581 120 40 HGNC:934 HGNC:2529 HGNC:933 Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use Amgen Inc. 08/09/212D 3D TSV
US10889552 29 29 HGNC:5253 Dihydroxybenzamide compound having HSP90 inhibitory activity or pharmaceutically acceptable salt thereof, and medical use thereof ONCOZEN CO.. LTD. 08/09/212D 3D TSV
US10889568 96 95 HGNC:12338 Inhibitors of TRPC6 Boehringer Ingelheim International GmbH 08/09/212D 3D TSV
US10888567 78 78 HGNC:6059 Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy Auckland UniServices Limited 08/09/212D 3D TSV
US10889591 69 69 HGNC:8795 PDE9 inhibitor and use thereof Nanjing TransThera Biosciences Co. Ltd. 08/09/212D 3D TSV
US10889571 217 215 Substituted benzoimidazoles and imidazo[4,5-c]pyridines for treating certain leukemias Terns, Inc. 08/09/212D 3D TSV
US10889555 279 268 Sulfonamide compound or salt thereof Taiho Pharmaceutical Co., Ltd. 08/09/212D 3D TSV
US10889564 52 52 HGNC:2867 Tetrahydroindazoles and medical uses thereof Genase Therapeutics B.V. 08/09/212D 3D TSV
US10889579 51 17 HGNC:934 HGNC:2529 HGNC:933 Thiazine derivatives as β-secretase inhibitors and methods of use Amgen Inc. 08/09/212D 3D TSV
US10889592 39 21 Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors VALO EARLY DISCOVERY, INC. 08/09/212D 3D TSV
US10889595 7 7 HGNC:933 [1,3]thiazin-2-amine compound, application, and pharmaceutical composition TETRANOV PHARMACEUTICAL CO., LTD. 08/09/212D 3D TSV
US10888550 33 33 HGNC:6819 Pyrazole derivatives as MALT1 inhibitors Janssen Pharmaceutica NV 08/08/212D 3D TSV
US10881668 12 6 HGNC:13575 HGNC:1105 Acetamide thienotriazolodiazepines and uses thereof Dana-Farber Cancer Institute, Inc. 08/01/212D 3D TSV
US10882857 17 17 HGNC:3357 Bicyclic compounds as ATX inhibitors Hoffmann-La Roche Inc. 08/01/212D 3D TSV
US10882838 177 61 HGNC:2160 Cannabinergic compounds and uses thereof NORTHEASTERN UNIVERSITY 08/01/212D 3D TSV
US10882844 48 48 Compounds useful as immunomodulators Bristol-Myers Squibb Company 08/01/212D 3D TSV
US10882835 27 27 HGNC:29079 KDM1A inhibitors for the treatment of disease Imago Biosciences, Inc. 08/01/212D 3D TSV
US10882859 12 3 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Kinase inhibitors TOPIVERT PHARMA LIMITED 08/01/212D 3D TSV
US10882829 88 22 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Pharmaceutical compounds Sareum Limited 08/01/212D 3D TSV
US10882833 17 16 Phenylate derivative, preparation method therefor, and pharmaceutical composition and uses thereof Institute of Materia Medica, Chinese Academy of Medical Sciences; Tianjin Chase Sun Pharmaceutical Co., LTD 08/01/212D 3D TSV
US10882866 148 137 Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors Boehringer Ingelheim International GmbH 08/01/212D 3D TSV
US10881652 2116 812 HGNC:9967 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array Biopharma Inc. 08/01/212D 3D TSV
US10882855 56 19 HGNC:3528 HGNC:3529 HGNC:3535 Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases ONO PHARMACEUTICAL CO., LTD. 08/01/212D 3D TSV
US10882853 12 8 HGNC:6307 HGNC:7029 Tyrosine kinase inhibitor and application thereof LaNova Medicines Limited 08/01/212D 3D TSV
US10870635 36 25 HGNC:934 HGNC:2529 HGNC:933 Compounds and their use as BACE1 inhibitors ALLGENESIS BIOTHERAPEUTICS, INC. 07/26/212D 3D TSV
US10870651 52 40 HGNC:3697 HGNC:1780 HGNC:16870 HGNC:1771 HGNC:16627 HGNC:11283 HGNC:9410 HGNC:19007 HGNC:9967 Inhibitors of cyclin-dependent kinase 7 (CDK7) Dana-Farber Cancer Institute, Inc. 07/26/212D 3D TSV
US10870660 278 138 HGNC:3023 HGNC:3024 Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect SHIONOGI & CO., LTD. 07/26/212D 3D TSV
US10870641 855 825 Pyridazinones as PARP7 inhibitors Ribon Therapeutics, Inc. 07/26/212D 3D TSV
US10870639 27 18 HGNC:3765 Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same HANMI PHARM. CO.. LTD. 07/26/212D 3D TSV
US10870625 10 10 HGNC:2861 Zwitterionic propargyl-linked antifolates useful for treating bacterial infections UNIVERSITY OF CONNECTICUT 07/26/212D 3D TSV
US10875847 13 9 HGNC:6190 HGNC:6192 HGNC:6193 Aminopyrazoles as selective janus kinase inhibitors Intervet Inc. 07/25/212D 3D TSV
US10875829 6 2 HGNC:11050 HGNC:11048 HGNC:11049 Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB 07/25/212D 3D TSV
US10864192 4 4 HGNC:108 Compositions and methods for inhibiting brain trauma-induced neurodegeneration and related conditions Aristea Translational Medicine Corporation 07/25/212D 3D TSV
US10869871 96 91 HGNC:5154 Compositions and methods of modulating short-chain dehydrogenase activity CASE WESTERN RESERVE UNIVERSITY; THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 07/25/212D 3D TSV
US10874634 43 23 HGNC:20581 HGNC:2603 Compounds and methods for inhibiting CYP26 enzymes Queen''s University at Kingston 07/25/212D 3D TSV
US10875867 202 90 HGNC:8772 Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide Boehringer Ingelheim International GmbH 07/25/212D 3D TSV
US10875851 183 174 HGNC:3530 Factor XIIa inhibitors MERCK SHARP & DOHME CORP. 07/25/212D 3D TSV
US10875852 156 151 HGNC:1133 Heteroaromatic compounds as BTK inhibitors Boehringer Ingelheim International GmbH 07/25/212D 3D TSV
US10874687 12 3 Highly active compounds against COVID-19 Atea Pharmaceuticals, Inc. 07/25/212D 3D TSV
US10870618 46 30 HGNC:4852 HGNC:4854 HGNC:4853 Histone deacetylase inhibitors and uses thereof MUSC FOUNDATION FOR RESEARCH DEVELOPMENT 07/25/212D 3D TSV
US10874683 39 26 N4-hydroxycytidine and derivatives and anti-viral uses related thereto Emory University 07/25/212D 3D TSV
US10874669 32 16 HGNC:3023 HGNC:3024 Neuroprotective agents for treatment of neurodegenerative diseases WAYNE STATE UNIVERSITY 07/25/212D 3D TSV
US10869929 22 22 Phosphonate linkers and their use to facilitate cellular retention of compounds MERCK SHARP & DOHME CORP. 07/25/212D 3D TSV
US10874675 34 34 HGNC:23357 Pteridine dione monocarboxylate transporter inhibitors THE SCRIPPS RESEARCH INSTITUTE 07/25/212D 3D TSV
US10875863 26 25 HGNC:10020 RIPK2 inhibitors and method of treating cancer with same UNIVERSITY HEALTH NETWORK 07/25/212D 3D TSV
US10875864 120 102 HGNC:6251 Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. 07/25/212D 3D TSV
US10875832 3 3 Substituted pyrimidines for treating bacterial infections FORGE THERAPEUTICS, INC. 07/25/212D 3D TSV
US10874640 138 136 Substituted pyrrolizine compounds and uses thereof GILEAD SCIENCES, INC. 07/25/212D 3D TSV
US10875854 35 34 Triazolopyridines Hoffmann-La Roche Inc. 07/25/212D 3D TSV
US10870623 23 23 Trifluoromethylpropanamide derivatives as HTRA1 inhibitors Hoffmann-La Roche Inc. 07/25/212D 3D TSV
US10865384 119 47 HGNC:2453 HGNC:2452 HGNC:6876 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis Agency for Science, Technology and Research; National University of Singapore 07/18/212D 3D TSV
US10865208 231 229 HGNC:16935 ATG7 inhibitors and the uses thereof MILLENNIUM PHARMACEUTICALS, INC. 07/18/212D 3D TSV
US10864248 3 3 Dab2 inhibitors for the prevention and treatment of cystic fibrosis TRUSTEES OF DARTMOUTH COLLEGE 07/18/212D 3D TSV
US10865182 17 17 Difluoroketamide derivatives as HtrA1 inhibitors Hoffmann-La Roche Inc. 07/18/212D 3D TSV
US10864201 57 57 Heteroaromatic compounds as Vanin inhibitors Boehringer Ingelheim International GmbH 07/18/212D 3D TSV
US10865206 15 15 HGNC:1778 Inhibitors of cyclin-dependent kinase 7 (CDK7) Syros Pharmaceuticals, Inc. 07/18/212D 3D TSV
US10864202 75 75 HGNC:29079 Inhibitors of lysine specific demethylase-1 Celgene Quanticel Research, Inc. 07/18/212D 3D TSV
US10865186 25 12 HGNC:8154 HGNC:8156 Opioid agonists and uses thereof Nektar Therapeutics 07/18/212D 3D TSV
US10865195 7 7 HGNC:10548 Pet imaging agents Novartis AG 07/18/212D 3D TSV
US10851050 39 39 Biaryl urea derivative or salt thereof and preparation process and use for the same FUDAN UNIVERSITY 07/13/212D 3D TSV
US10849881 117 116 HGNC:10548 Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl Hoffmann-La Roche Inc. 07/13/212D 3D TSV
US10849901 159 140 Arf6 inhibitors and methods of synthesis and use thereof Navigen, Inc.; The University of Utah Research Foundation 07/12/212D 3D TSV
US10851083 186 185 Benzoimidazoles as prolyl hydroxylase inhibitors Janssen Pharmaceutica NV 07/12/212D 3D TSV
US10849883 380 377 HGNC:2771 Benzopyrazole compounds and analogues thereof BioCryst Pharmaceuticals, Inc. 07/12/212D 3D TSV
US10851091 62 21 HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 Benzoxazepin oxazolidinone compounds and methods of use Genentech, Inc. 07/12/212D 3D TSV
US10851116 188 43 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Bicyclic amines as novel JAK kinase inhibitors LEO Pharma A/S 07/12/212D 3D TSV
US10851105 96 12 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Bicyclic heterocycles as FGFR4 inhibitors Incyte Corporation 07/12/212D 3D TSV
US10849982 64 64 HGNC:2717 C3-carbon linked glutarimide degronimers for target protein degradation C4 Therapeutics, Inc. 07/12/212D 3D TSV
US10851110 95 92 Heterocyclic inhibitors of PTPN11 BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 07/12/212D 3D TSV
US10851102 162 52 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Imidazole and triazole containing bicyclic compounds as JAK inhibitors Theravance Biopharma R&D IP, LLC 07/12/212D 3D TSV
US10851089 32 30 HGNC:7158 Matrix metalloproteinase (MMP) inhibitors and methods of use thereof Foresee Pharmaceuticals Co., Ltd. 07/12/212D 3D TSV
US10851080 31 31 HGNC:8031 Methods of treatment using pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds Array Biopharma Inc. 07/12/212D 3D TSV
US10851092 6 3 HGNC:9967 Pyridine compound Daiichi Sankyo Company, Limited 07/12/212D 3D TSV
US10851082 434 227 HGNC:7110 HGNC:7111 Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2) Northwestern University 07/12/212D 3D TSV
US10851108 7 7 HGNC:6255 Substituted bicyclic heterocyclic compounds Bristol-Myers Squibb Company 07/12/212D 3D TSV
US10849898 122 118 HGNC:29079 Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas CELGENE QUANTICEL RESEARCH, INC. 07/12/212D 3D TSV
US10858342 226 112 HGNC:2592 HGNC:2591 Bicyclic imidazole derivatives useful for the treatment of renal diseases, cardiovascular diseases and fibrotic diseases Boehringer Ingelheim International GmbH 07/11/212D 3D TSV
US10857082 27 26 Diarylalkanes as potent inhibitors of binuclear enzymes Unigen, Inc. 07/11/212D 3D TSV
US10858323 12 3 HGNC:4852 HGNC:14064 HGNC:4854 HGNC:4853 HDAC inhibitors for the treatment of diabetic peripheral neuropathy REGENACY PHARMACEUTICALS, LLC 07/11/212D 3D TSV
US10858359 6 6 HGNC:9644 Heterocyclic ring derivatives useful as SHP2 inhibitors JACOBIO PHARMACEUTICALS CO., LTD. 07/11/212D 3D TSV
US10858373 106 53 HGNC:17038 Heterocyclic spiro compounds as MAGL inhibitors Pfizer Inc. 07/11/212D 3D TSV
US10858344 20 20 HGNC:3078 Hydantoin containing deoxyuridine triphosphatase inhibitors CV6 Therapeutics (NI) Limited 07/11/212D 3D TSV
US10858364 15 3 HGNC:3432 HGNC:3430 HGNC:1079 HGNC:1057 HGNC:1133 HGNC:6193 HGNC:6171 HGNC:11719 HGNC:12434 HGNC:3236 Imidazopyrazine inhibitors of Bruton's tyrosine kinase Acerta Pharma B.V. 07/11/212D 3D TSV
US10858362 311 111 HGNC:8775 HGNC:8774 HGNC:8776 Imidazopyrazinones as PDE1 inhibitors H. Lundbeck A/S 07/11/212D 3D TSV
US10858355 37 34 HGNC:8978 Inhibitors of phosphatidylinositol 3-kinase gamma AstraZeneca AB 07/11/212D 3D TSV
US10858368 22 22 HGNC:5302 Modulators of the 5-hydroxytryptamine receptor 7 and their method of use TEMPLE UNIVERSITY—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION; PRAEVENTIX, LLC 07/11/212D 3D TSV
US10858326 5 5 HGNC:17734 Oxazoline pseudodimers, pharmaceutical compositions and the use thereof PURDUE PHARMA L.P. 07/11/212D 3D TSV
US10858356 80 80 HGNC:4324 Pyrazolopyridine derivative having GLP-1 receptor agonist effect Chugai Seiyaku Kabushiki Kaisha 07/11/212D 3D TSV
US10858316 146 98 HGNC:6943 Small molecule inhibitors of the MCL-1 oncoprotein and uses thereof UNIVERSITY OF MARYLAND, BALTIMORE 07/11/212D 3D TSV
US10858365 518 119 HGNC:268 HGNC:262 HGNC:263 HGNC:264 Triazolo-pyrimidine compounds and uses thereof TBA 07/11/212D 3D TSV
US10858366 71 41 Tricyclic compounds useful to treat orthomyxovirus infections Novartis AG 07/11/212D 3D TSV
US10844038 134 16 HGNC:11283 HGNC:8980 HGNC:8979 HGNC:6877 HGNC:8978 HGNC:6735 HGNC:4037 HGNC:6871 HGNC:3942 HGNC:8977 HGNC:9967 HGNC:3765 HGNC:6171 HGNC:11393 HGNC:12841 HGNC:9617 HGNC:3432 HGNC:6844 HGNC:4840 HGNC:3697 HGNC:6845 HGNC:1079 HGNC:6846 HGNC:1057 HGNC:1133 HGNC:6847 HGNC:16627 HGNC:1097 HGNC:6342 HGNC:3955 HGNC:6840 HGNC:2444 HGNC:6842 HGNC:6524 HGNC:6843 1,2-dithiolane compounds useful in neuroprotection, autoimmune and cancer diseases and conditions SABILA BIOSCIENCES LLC 07/06/212D 3D TSV
US10844056 73 63 HGNC:5253 Fused amino pyridine as HSP90 inhibitors Curis, Inc. 07/06/212D 3D TSV
US10844067 255 86 HGNC:6307 HGNC:9967 Heterocyclic compounds as RET kinase inhibitors Cancer Research Technology Limited 07/06/212D 3D TSV
US10842803 100 100 HGNC:11491 Imidazopyridines Syk inhibitors KRONOS BIO, INC. 07/06/212D 3D TSV
US10844057 52 13 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Process for preparing JAK inhibitors and intermediates thereof Theravance Biopharma R&D IP, LLC 07/06/212D 3D TSV
US10844062 94 92 HGNC:6307 Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof Incheon University Industry Academic Cooperation Foundation; Samjin Pharmaceutical Co., Ltd.; Bamichem Co., Ltd. 07/06/212D 3D TSV
US10844069 438 146 HGNC:7027 HGNC:12446 Pyrrolotriazine compounds as TAM inhibitors Incyte Corporation 07/06/212D 3D TSV
US10842799 110 107 HGNC:6871 Serine/threonine kinase inhibitors GENENTECH, INC. 07/06/212D 3D TSV
US10844032 286 271 HGNC:990 Substituted benzofuran, benzothiophene and indole Mcl-1 inhibitors Vanderbilt University 07/06/212D 3D TSV
US10844077 44 22 HGNC:4840 HGNC:1133 Thiazolyl-containing compounds for treating proliferative diseases Dana-Farber Cancer Institute, Inc. 07/06/212D 3D TSV
US10844044 364 359 HGNC:12757 WDR5 inhibitors and modulators Vanderbilt University 07/06/212D 3D TSV
US10836763 48 12 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 5 to 7 membered heterocyclic amides as JAK inhibitors Theravance Biopharma R&D IP, LLC 06/30/212D 3D TSV
US10836764 164 55 HGNC:5295 HGNC:5294 5-HT2C receptor agonists and compositions and methods of use Arena Pharmaceuticals, Inc. 06/30/212D 3D TSV
US10836773 6 6 HGNC:7056 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds Eli Lilly and Company 06/30/212D 3D TSV
US10836758 75 73 HGNC:10597 Acyl sulfonamide NaV1.7 inhibitors BRISTOL-MYERS SQUIBB COMPANY 06/30/212D 3D TSV
US10829489 98 57 HGNC:8810 Bicyclic heterocyclic derivatives Merck Patent GmbH 06/30/212D 3D TSV
US10836743 110 58 HGNC:6833 HGNC:6834 HGNC:29079 Fluorinated cyclopropylamine compound, preparation method therefor, pharmaceutical composition thereof, and uses thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES 06/30/212D 3D TSV
US10836720 24 13 HGNC:6153 Inhibitors of integrin alpha 5 beta 1 and methods of use The Regents of the University of California 06/30/212D 3D TSV
US10836768 205 47 HGNC:11526 HGNC:6251 HGNC:11527 HGNC:11528 N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists Ogeda SA 06/30/212D 3D TSV
US10836742 15 15 N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals Neomed Institute 06/30/212D 3D TSV
US10836741 13 12 Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors Valo Early Discovery, Inc. 06/30/212D 3D TSV
US10836728 22 11 HGNC:711 HGNC:8156 Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same Mebias Discovery, Inc. 06/30/212D 3D TSV
US10836769 56 55 Substituted pyrrolizine compounds and uses thereof GILEAD SCIENCES, INC. 06/30/212D 3D TSV
US10835536 52 50 HGNC:3689 Therapeutic agent for FGFR inhibitor-resistant cancer Taiho Pharmaceutical Co., Ltd. 06/30/212D 3D TSV
US10829488 46 22 N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors THE REGENTS OF THE UNIVERSITY OF MICHIGAN 06/29/212D 3D TSV
US10828301 51 51 HGNC:11491 2,4-pyrimidinediamine compounds and their uses Rigel Pharmceuticals, Inc. 06/28/212D 3D TSV
US10829480 296 153 HGNC:8155 HGNC:8156 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-l,3-diaza-spiro-[4.5]-decane derivatives GRUENENTHAL GMBH 06/28/212D 3D TSV
US10829478 698 150 HGNC:7160 HGNC:195 HGNC:7159 HGNC:220 HGNC:221 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis GALAPAGOS NV 06/28/212D 3D TSV
US10829492 73 50 HGNC:6192 HGNC:8031 HGNC:8032 HGNC:8033 Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.; CENTAURUS BIOPHARMA CO., LTD.; LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. 06/28/212D 3D TSV
US10829446 156 155 Aryl sulfonohydrazides MONASH UNIVERSITY; The Walter and Eliza Hall Institute of Medical Research 06/28/212D 3D TSV
US10829481 189 189 Benzimidazole derivatives as modulators of ROR-gamma Vitae Pharmaceuticals, LLC 06/28/212D 3D TSV
US10829487 150 149 Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors Boehringer Ingelheim International GmbH 06/28/212D 3D TSV
US10829493 69 23 HGNC:6342 Compositions and methods for treating KIT- and PDGFRA-mediated diseases Blueprint Medicines Corporation 06/28/212D 3D TSV
US10828299 7 7 HGNC:11491 Crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine KRONOS BIO, INC. 06/28/212D 3D TSV
US10829438 7 7 Neprilysin inhibitors Theravance Biopharma R&D IP, LLC 06/28/212D 3D TSV
US10829500 5 5 HGNC:933 Pyridyl-triazabicycles Hoffmann-La Roche Inc. 06/28/212D 3D TSV
US10829502 125 82 HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 Pyrimidinones as PI3K inhibitors Incyte Corporation; Incyte Holdings Corporation 06/28/212D 3D TSV
US10829491 22 22 HGNC:1133 Pyrimido[5,4-B]indolizine or pyrimido[5,4-B]pyrrolizine compound, preparation method and use thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACAD 06/28/212D 3D TSV
US10828300 248 244 HGNC:1133 Substituted 2,4-diaminopyrimidines as kinase inhibitors Celgene CAR LLC 06/28/212D 3D TSV
US10829448 121 111 Substituted benzoimidazoles as modulators of ROR-γ Vitae Pharmaceuticals, LLC 06/28/212D 3D TSV
US10829490 71 9 HGNC:1780 HGNC:1771 HGNC:1777 HGNC:1774 HGNC:1773 HGNC:1775 Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents GI Therapeutics, Inc. 06/28/212D 3D TSV
US10828290 327 108 HGNC:19310 HGNC:8987 Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors Incyte Corporation; Incyte Holdings Corporation 06/28/212D 3D TSV
US10829496 29 27 HGNC:17967 Thienopyridines and benzothiophenes useful as IRAK4 inhibitors Bristol-Myers Squibb Company 06/28/212D 3D TSV
US10829483 103 103 HGNC:17989 Thiophene, manufacturing method thereof, and pharmaceutical application of same CSTONE PHARMACEUTICAL (SUZHOU) CO., LTD.; CSTONE PHARMACEUTICALS (SHANGHAI) CO., LTD.; CSTONE PHARMACEUTICALS 06/28/212D 3D TSV
US10822352 718 703 HGNC:2771 Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders Achillion Pharmaceuticals, Inc. 06/21/212D 3D TSV
US10822319 2 2 Crystal of DPP-IV long-acting inhibitor and salt CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.; LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD.; CENTAURUS BIOPHARMA CO., LTD. 06/21/212D 3D TSV
US10822334 60 30 HGNC:3430 HGNC:3236 ErbB receptor inhibitors TBA 06/21/212D 3D TSV
US10822348 937 789 Inhibitors of Bruton's tyrosine kinase and methods of their use Janssen Pharmaceutica NV 06/21/212D 3D TSV
US10822345 64 63 HGNC:6221 KV1.3 inhibitors and their medical application 4SC AG 06/21/212D 3D TSV
US10822331 4 1 HGNC:882 Processes for preparing ATR inhibitors VERTEX PHARMACEUTICALS INCORPORATED 06/21/212D 3D TSV
US10822341 148 37 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Pyrazolo[1,5-a]pyrazin-4-yl derivatives Pfizer Inc. 06/21/212D 3D TSV
US10822342 12 12 HGNC:6853 Pyrazolopyrimidine derivatives as NIK inhibitors Janssen Pharmaceutica NV 06/21/212D 3D TSV
US10822338 75 74 HGNC:263 Substituted aminoquinazoline compounds as A2A antagonist Merck Sharp & Dohme Corp. 06/21/212D 3D TSV
US10821115 969 797 Compounds that inhibit Mcl-1 protein AMGEN INC. 06/20/212D 3D TSV
US10815234 116 115 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. 06/14/212D 3D TSV
US10815244 10 10 HGNC:3236 Isoidide derivatives and methods of making and using same RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 06/14/212D 3D TSV
US10815241 10 10 HGNC:7010 Optically active azabicyclo ring derivative Sumitomo Dainippon Pharma Co., Ltd. 06/14/212D 3D TSV
US10813932 120 31 HGNC:11491 HGNC:11283 HGNC:4617 HGNC:4616 HGNC:20790 HGNC:6874 HGNC:6876 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors Respivert Limited 06/13/212D 3D TSV
US10815215 268 215 HGNC:2867 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH BAYER AKTIENGESELLSCHAFT; BAYER PHARMA AKTIENGELLSCHAFT; THE BROAD INSTITUTE, INC.; PRESIDENT AND FELLOWS OF HARVARD COLLEGE; THE GENERAL HOSPITAL CORPORATION 06/13/212D 3D TSV
US10815229 1146 325 HGNC:10593 HGNC:10585 HGNC:10596 Benzenesulfonamide compounds and their use as therapeutic agents Xenon Pharmaceuticals Inc. 06/13/212D 3D TSV
US10815213 190 140 HGNC:1133 HGNC:3236 Bruton's tyrosine kinase inhibitors Pfizer Inc. 06/13/212D 3D TSV
US10815208 4 4 Method for preparing 2-hydroxyl-4-(2, 3-disubstituted benzyloxy)-5-substituted benzaldehyde derivative Institute of Materia Medica, Chinese Academy of Medical Sciences; Tianjin Chase Sun Pharmaceutical Co., LTD 06/13/212D 3D TSV
US10815206 95 90 RIP1 inhibitory compounds and methods for making and using the same Rigel Pharmaceuticals, Inc. 06/13/212D 3D TSV
US10813930 107 107 HGNC:3690 Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 Incyte Corporation; Incyte Holdings Corporation 06/13/212D 3D TSV
US10813942 17 17 HGNC:742 Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR Pfizer Inc. 06/13/212D 3D TSV
US10806718 605 192 HGNC:8775 HGNC:8774 HGNC:8776 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors H. Lundbeck A/S 06/11/212D 3D TSV
US10807988 693 382 HGNC:8155 HGNC:8156 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives Grünenthal GmbH 06/11/212D 3D TSV
US10807989 571 289 HGNC:8155 HGNC:8156 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives GRÜNENTHAL GMBH 06/11/212D 3D TSV
US10807982 105 104 HGNC:13575 Bromodomain inhibitors Celgene Quanticel Research, Inc. 06/11/212D 3D TSV
US10806724 59 59 HGNC:4594 Chromane, isochromane and dihydroisobenzofuran derivatives as mGluR2-negative allosteric modulators, compositions, and their use Merck Sharp & Dohme Corp. 06/11/212D 3D TSV
US10807985 169 124 Compositions useful for treating disorders related to kit Blueprint Medicines Corporation 06/11/212D 3D TSV
US10807952 101 101 HGNC:2771 Compounds for treatment of immune inflammatory disorders Achillion Pharmaceuticals, Inc. 06/11/212D 3D TSV
US10807993 63 51 HGNC:6251 Dihydrochromene derivatives Sumitomo Dainippon Pharma Co., Ltd. 06/11/212D 3D TSV
US10807980 220 156 Dihydropyrrolopyridine inhibitors of ROR-gamma Vitae Pharmaceuticals, LLC 06/11/212D 3D TSV
US10807986 522 200 HGNC:9967 Fused pyrimidine compound or salt thereof Taiho Pharmaceutical Co., Ltd. 06/11/212D 3D TSV
US10807944 144 42 HGNC:4852 HGNC:14064 HGNC:13315 HGNC:4854 HGNC:4853 HDAC inhibitor compounds and methods of treatment University of Florida Research Foundation, Inc.; The Scripps Research Institute 06/11/212D 3D TSV
US10807994 99 97 HGNC:12761 Heterocyclic compounds and uses thereof NUVATION BIO INC. 06/11/212D 3D TSV
US10807966 27 16 HGNC:10251 HGNC:10252 Heterocyclic compounds as kinase inhibitors Translational Drug Development, LLC 06/11/212D 3D TSV
US10807956 210 101 HGNC:9886 HGNC:17071 HGNC:18039 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. 06/11/212D 3D TSV
US10806785 205 191 Immunomodulator compounds and methods of use Incyte Corporation 06/11/212D 3D TSV
US10807974 309 161 HGNC:6833 HGNC:6834 HGNC:80 HGNC:6666 Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer The Institute of Cancer Research: Royal Cancer Hospital 06/11/212D 3D TSV
US10806794 28 28 Protease inhibitors having enhanced features Nektar Therapeutics 06/11/212D 3D TSV
US10807971 68 17 HGNC:16672 HGNC:3009 Pyrrolidinone compounds Eli Lilly and Company 06/11/212D 3D TSV
US10806720 76 51 HGNC:644 Selective androgen receptor degrader (SARD) ligands and methods of use thereof University of Tennessee Research Foundation 06/11/212D 3D TSV
US10807991 122 42 HGNC:3167 HGNC:3165 HGNC:14299 Spiro-cyclic amine derivatives as S1P modulators AbbVie B.V.; AbbVie, Inc. 06/11/212D 3D TSV
US10807959 266 260 HGNC:12757 WDR5-MLL1 inhibitors and modulators Vanderbilt University 06/11/212D 3D TSV
US10800755 217 38 HGNC:3023 HGNC:5286 HGNC:6251 2,6-disubstituted pyridine derivative SUMITOMO DAINIPPON PHARMA CO., LTD. 06/01/212D 3D TSV
US10800739 37 20 HGNC:270 HGNC:272 4-carboxamido-isoindolinone derivatives as selective PARP-1 inhibitors NERVIANO MEDICAL SCIENCES S.R.L. 06/01/212D 3D TSV
US10799507 607 155 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5-azaspiro[2.5]octane-8-carboxylic acid derivatives as novel JAK kinase inhibitors Leo Pharma A/S 06/01/212D 3D TSV
US10800725 60 20 Arylpropionyl-triketone antibacterial agents TBA 06/01/212D 3D TSV
US10800778 120 40 Beta-lactamase inhibitor compounds Entasis Therapeutics Limited 06/01/212D 3D TSV
US10800786 33 32 HGNC:10548 Bicyclic compounds as ATX inhibitors Hoffman-La Roche Inc. 06/01/212D 3D TSV
US10800783 433 218 HGNC:1771 CDK2/4/6 inhibitors Pfizer Inc. 06/01/212D 3D TSV
US10800761 113 105 HGNC:6863 Carboxamide compounds and uses thereof Incyte Corporation 06/01/212D 3D TSV
US10799494 22 22 Combination of respiratory electron transport chain inhibitors with a cytochrome bd inhibitor TBA 06/01/212D 3D TSV
US10799605 13 7 HGNC:8039 Conjugate comprising a neurotensin receptor ligand and use thereof 3B Pharmaceuticals GMBH 06/01/212D 3D TSV
US10800776 45 25 HGNC:4594 HGNC:6251 Fluorine-containing triazolopyridine, and manufacturing method, pharmaceutical composition, and application thereof Shanghai Institute of Materia Medica, Chinese Academy of Sciences 06/01/212D 3D TSV
US10800779 138 138 HGNC:29079 Heterocyclic compounds as LSD1 inhibitors Incyte Corporation 06/01/212D 3D TSV
US10800768 271 266 Heterocyclic compounds as immunomodulators Incyte Corporation 06/01/212D 3D TSV
US10800769 265 122 HGNC:1925 Heterocyclic inhibitors of ATR kinase Board of Regents, The University of Texas System; ChemPartner Corporation 06/01/212D 3D TSV
US10800774 64 32 HGNC:1925 Heterocyclic inhibitors of ATR kinase Board of Regents, The University of Texas System; ChemPartner Corporation 06/01/212D 3D TSV
US10800804 26 12 HGNC:6561 HGNC:6563 Hybrid galactoside inhibitor of galectins TBA 06/01/212D 3D TSV
US10800744 41 41 HGNC:3827 Imidazole derivatives as formyl peptide receptor modulators ALLERGAN, INC. 06/01/212D 3D TSV
US10800765 63 62 HGNC:4502 Indole derivative used as CRTH2 inhibitor CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. 06/01/212D 3D TSV
US10800792 937 912 HGNC:1133 Inhibitors of Bruton's tyrosine kinase and method of their use Janssen Pharmaceutica NV 06/01/212D 3D TSV
US10800757 96 94 HGNC:12338 Inhibitors of TRPC6 Boehringer Ingelheim International GmbH; Hydra Biosciences, LLC 06/01/212D 3D TSV
USRE48253 9 9 HGNC:12576 Methotrexate adjuvants to reduce toxicity and methods for using the same Tosk, Inc. 06/01/212D 3D TSV
US10800784 246 123 HGNC:8809 HGNC:8810 Nitrogen-containing heterocyclic amide compound and pharmaceutical use thereof JAPAN TOBACCO INC. 06/01/212D 3D TSV
US10800746 22 11 HGNC:897 HGNC:895 Oxoalkyl-substituted phenyltriazole derivatives and uses thereof BAYER PHARMA AKTIENGESELLSCHAFT 06/01/212D 3D TSV
US10800775 14 7 HGNC:6190 Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same ACLARIS THERAPEUTICS, INC. 06/01/212D 3D TSV
US10800764 23 6 Substituted pyridine derivatives useful as C-FMS kinase inhibitors Janssen Pharmaceutica NV 06/01/212D 3D TSV
US10800785 97 85 HGNC:1133 Substituted pyrrolo[2,3-d]pyridazin-4-ones and pyrazolo[3,4-d]pyridazin-4-ones as protein kinase inhibitors Shanghai Fochon Pharmaceutical Co., Ltd.; Fochon Pharmaceuticals, Ltd. 06/01/212D 3D TSV
US10800753 7 7 HGNC:23 Tetrahydrothiophene-based GABA aminotransferase inactivators and analogs thereof for treating neurological disorders Northwestern University 06/01/212D 3D TSV
US10800767 82 36 HGNC:11799 HGNC:11796 Thyroid hormone receptor beta agonist compounds Terns, Inc. 06/01/212D 3D TSV
US10799518 188 179 HGNC:3827 Use of agonists of formyl peptide receptor 2 for treating dermatological diseases ALLERGAN, INC. 06/01/212D 3D TSV
US10793561 2 2 HGNC:262 1,8-naphthyridinone compounds and uses thereof NUVATION BIO INC. 05/14/212D 3D TSV
US10793528 143 73 HGNC:8156 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives GRÜNENTHAL GMBH 05/14/212D 3D TSV
US10793556 178 34 HGNC:8155 HGNC:8156 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives GRUENENTHAL GMBH 05/14/212D 3D TSV
US10793564 145 144 HGNC:6161 Amino acid compounds and methods of use PLIANT THERAPEUTICS, INC. 05/14/212D 3D TSV
US10793552 3 3 HGNC:550 Amino pyrimidine ssao inhibitors ELI LILLY AND COMPANY 05/14/212D 3D TSV
US10793582 85 84 HGNC:17929 Bicyclic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION 05/14/212D 3D TSV
US10793567 30 15 HGNC:4852 HGNC:4853 Bicyclic inhibitors of histone deacetylase Rodin Therapeutics, Inc. 05/14/212D 3D TSV
US10793579 370 361 HGNC:17967 Bicyclic-fused heteroaryl or aryl compounds Pfizer Inc. 05/14/212D 3D TSV
US10793566 134 123 HGNC:6735 HGNC:1057 HGNC:1133 HGNC:3236 HGNC:6524 Bruton's tyrosine kinase inhibitors ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO. LTD.; SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES 05/14/212D 3D TSV
US10793576 128 126 HGNC:1133 Compound used as Bruton's tyrosine kinase inhibitor and preparation method and application thereof CHENGDU BRILLIANT PHARMACEUTICAL CO., LTD.; CHENGDU HIGHBRED PHARMACEUTICAL CO., LTD. 05/14/212D 3D TSV
US10793563 532 502 HGNC:19687 GCN2 inhibitors and uses thereof MERCK PATENT GMBH; VERTEX PHARMACEUTICALS INCORPORATED 05/14/212D 3D TSV
US10793514 38 19 HGNC:10943 Glutamine transport inhibitors and methods for treating cancer Vanderbilt University 05/14/212D 3D TSV
US10793565 4 4 Heterocyclic compounds as immunomodulators Incyte Corporation 05/14/212D 3D TSV
US10793535 51 45 Heterocyclic glutaminase inhibitors Calithera Biosciences, Inc. 05/14/212D 3D TSV
US10793568 340 336 HGNC:7967 Hormone receptor modulators for treating metabolic conditions and disorders ARDELYX, INC. 05/14/212D 3D TSV
US10793575 89 59 HGNC:1133 Oxoisoquinoline derivatives CARNA BIOSCIENCES, INC. 05/14/212D 3D TSV
US10792283 7 7 HGNC:8977 Quinoline analogs as phosphatidylinositol 3-kinase inhibitors HANGZHOU ZHENGXIANG PHARMACEUTICALS CO., LTD. 05/14/212D 3D TSV
US10793545 22 22 HGNC:17967 Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs Bayer Pharma Aktiengesellschaft 05/14/212D 3D TSV
US10793591 16 15 Substituted nucleosides, nucleotides and analogs thereof Janssen BioPharma, Inc. 05/14/212D 3D TSV
US10793580 310 310 HGNC:8783 Substituted pyrazoloazepin-8-ones and their use as phosphodiesterase inhibitors LEO Pharma A/S 05/14/212D 3D TSV
US10793529 4 4 HGNC:9602 Substituted pyridazines and 1,2,4-triazines as prostacyclin receptor modulators ARENA PHARMACEUTICALS, INC. 05/14/212D 3D TSV
US10793549 63 59 Sulfuryl-substituted benzoheterocyclic derivative, preparation method and medical use thereof SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD.; YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. 05/14/212D 3D TSV
US10793574 218 217 TYK2 inhibitors and uses thereof Nimbus Lakshmi, Inc. 05/14/212D 3D TSV
US10787452 579 555 HGNC:882 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED 05/11/212D 3D TSV
US10787435 57 56 HGNC:6857 ASK1 inhibitor and preparation method and use thereof Fuijan Cosunter Pharmaceutical Co. Ltd. 05/09/212D 3D TSV
US10787434 9 9 HGNC:10894 Benzopiperdine derivatives and their use in the treatment of cancer and hemoglobinopathies CTXT PTY, LTD 05/09/212D 3D TSV
US10787459 13 3 HGNC:10548 Bicyclic compounds as ATX inhibitors Hoffmann-La Roche Inc. 05/09/212D 3D TSV
US10787419 92 90 Cannabinoid receptor mediating iminopyrazole compounds The United States of America, as represented by the Secretary, Department of Health and Human Services 05/09/212D 3D TSV
US10787457 78 78 HGNC:9967 Fused pyrimidine compound or salt thereof Taiho Pharmaceutical Co., Ltd. 05/09/212D 3D TSV
US10787436 82 40 HGNC:1780 HGNC:1771 HGNC:1778 HGNC:6881 HGNC:1722 HGNC:6112 HGNC:6850 HGNC:1779 HGNC:1774 HGNC:6886 Inhibitors of cyclin-dependent kinase 7 (CDK7) Dana-Farber Cancer Institute, Inc. 05/09/212D 3D TSV
US10787453 2 2 HGNC:9922 Octahydropyrrolopyrroles their preparation and use The Trustees of Columbia University in the City of New York 05/09/212D 3D TSV
US10787472 23 23 HGNC:10582 Prodrugs of pyridone amides useful as modulators of sodium channels Vertex Pharmaceuticals Incorporated 05/09/212D 3D TSV
US10787450 255 253 HGNC:10252 Spiro-fused cyclic ureas as inhibitors of rock Bristol-Myers Squibb Company 05/09/212D 3D TSV
US10787438 40 18 Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors Pfizer Inc. 05/09/212D 3D TSV
US10787425 105 105 HGNC:5154 Thiazolidinedione derivative and use thereof INDUSTRY-ACADEMIC COOPERATION FOUNDATION CHOSUN UNIVERSITY 05/09/212D 3D TSV
US10781209 196 93 HGNC:13575 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins Incyte Corporation 05/03/212D 3D TSV
US10781212 4 2 2,6-diamino pyridine compounds Eli Lilly and Company 05/03/212D 3D TSV
US10781180 4 4 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto Arena Pharmaceuticals, Inc. 05/03/212D 3D TSV
US10781202 10 10 HGNC:8781 Azetidinyloxyphenylpyrrolidine compounds Eli Lilly and Company 05/03/212D 3D TSV
US10781182 12 6 HGNC:7463 Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A. 05/03/212D 3D TSV
US10781185 149 108 HGNC:17270 Heterocyclic compounds for the inhibition of PASK BioEnergenix LLC 05/03/212D 3D TSV
US10781181 216 108 HGNC:6371 HGNC:6357 N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors KALVISTA PHARMACEUTICALS LIMITED 05/03/212D 3D TSV
US10781211 677 260 HGNC:17038 Spirocycle compounds and methods of making and using same LUNDBECK LA JOLLA RESEARCH CENTER, INC. 05/03/212D 3D TSV
US10781204 378 163 HGNC:6192 HGNC:12440 TYK2 inhibitors and uses thereof Nimbus Lakshmi, Inc. 05/03/212D 3D TSV
US10781200 140 137 HGNC:6371 Therapeutic inhibitory compounds ATTUNE PHARMACEUTICALS, INC. 05/03/212D 3D TSV
US10780095 30 25 HGNC:15836 Compositions and methods for treating disorders of circadian and diurnal rhythms using prokineticin 2 agonists and antagonists THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 05/02/212D 3D TSV
US10780092 156 151 HGNC:4685 Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators Merck Sharp & Dohme Corp. 05/02/212D 3D TSV
US10780090 537 352 HGNC:30660 Heteroaryl compounds useful as inhibitors of SUMO activating enzyme Millennium Pharmaceuticals, Inc. 05/02/212D 3D TSV
US10780082 18 3 HGNC:427 Macrocycle and composition comprising thereof Shenzhen TargetRx, Inc. 05/02/212D 3D TSV
US10780078 21 7 HGNC:8153 HGNC:8155 HGNC:8156 Mu opioid receptor modulators THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; FRIEDRICH-ALEXANDER-UNIVERSITÄT; THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 05/02/212D 3D TSV
US10781171 288 287 HGNC:4501 Substituted pyrrolidines as G-protein coupled receptor 43 agonists Epics Therapeutics 05/02/212D 3D TSV
US10766893 768 242 HGNC:8775 HGNC:8774 HGNC:8776 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors H. Lundbeck A/S 04/26/212D 3D TSV
US10766881 246 83 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases Array Biopharma Inc. 04/26/212D 3D TSV
US10766883 18 9 HGNC:6190 HGNC:6192 Aminopyrazoles as janus kinase inhibitors Merck Sharp & Dohme Corp. 04/26/212D 3D TSV
US10766894 52 13 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Aza-indazole compounds for use in tendon and/or ligament injuries NOVARTIS AG 04/26/212D 3D TSV
US10766884 294 137 HGNC:1773 Cyclin dependent kinase inhibitors Pfizer Inc. 04/26/212D 3D TSV
US10766897 213 155 HGNC:6251 HGNC:550 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PROXIMAGEN, LLC 04/26/212D 3D TSV
US10766864 106 106 HGNC:8156 Morphinan derivatives for the treatment of neuropathic pain Nektar Therapeutics 04/26/212D 3D TSV
US10766903 245 243 HGNC:12630 Piperidine derivatives as inhibitors of ubiquitin specific protease 7 ALMAC DISCOVERY LIMITED 04/26/212D 3D TSV
US10766858 25 19 HGNC:10597 Substituted benzamides and methods of use thereof GENENTECH, INC.; XENON PHARMACEUTICALS INC. 04/26/212D 3D TSV
US10766878 63 33 HGNC:497 Sulfonylcycloalkyl carboxamide compounds Genentech, Inc. 04/26/212D 3D TSV
US10765676 43 43 HGNC:8031 Trk-inhibiting compound ONO PHARMACEUTICAL CO., LTD. 04/26/212D 3D TSV
US10766902 96 96 HGNC:12761 Wee-1 inhibiting pyrazolopyrimidinone compounds ALMAC DISCOVERY LIMITED 04/26/212D 3D TSV
US10774065 22 22 HGNC:9644 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 NOVARTIS AG 04/25/212D 3D TSV
US10772893 488 432 2-(morpholin-4-yl)-1,7-naphthyridines BAYER PHARMA AKTIENGESELLSCHAFT 04/25/212D 3D TSV
US10774070 79 39 HGNC:9967 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors BLUEPRINT MEDICINES CORPORATION 04/25/212D 3D TSV
US10774051 1232 1204 HGNC:8537 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same SHIONOGI & CO., LTD. 04/25/212D 3D TSV
US10774068 200 123 HGNC:11408 HGNC:11406 Composition and methods for inhibiting mammalian sterile 20-like kinase 1 THE SCRIPPS RESEARCH INSTITUTE; UNIVERSITÄT BREMEN 04/25/212D 3D TSV
US10774069 4 3 HGNC:6666 Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making PHARMAKEA, INC. 04/25/212D 3D TSV
US10774054 16 8 HGNC:7967 FXR (NR1H4) modulating compounds Gilead Sciences, Inc. 04/25/212D 3D TSV
US10774102 106 106 HGNC:6563 Galactoside inhibitor of galectins Galecto Biotech AB 04/25/212D 3D TSV
US10774053 706 352 HIV protease inhibitors Gilead Sciences, Inc. 04/25/212D 3D TSV
US10774052 194 191 HGNC:3691 Heteroaryl compounds and uses thereof Celgene CAR LLC; Sanofi 04/25/212D 3D TSV
US10752635 54 54 HGNC:6863 Indazole compounds and uses thereof Incyte Corporation 04/25/212D 3D TSV
US10774063 26 24 HGNC:10289 Materials and method for inhibiting replication protein A and uses thereof Indiana University Research and Technology Corporation 04/25/212D 3D TSV
US10774085 105 105 HGNC:8031 Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds ARRAY BIOPHARMA INC. 04/25/212D 3D TSV
US10774071 762 381 PD-1/PD-L1 inhibitors Gilead Sciences, Inc. 04/25/212D 3D TSV
US10774056 197 71 HGNC:4852 HGNC:6251 HGNC:4854 HGNC:4853 Substituted piperazines as selective HDAC1,2 inhibitors REGENACY PHARMACEUTICALS, INC. 04/25/212D 3D TSV
US10774092 345 343 HGNC:12558 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES; SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE; YALE UNIVERSITY 04/25/212D 3D TSV
US10759805 43 43 HGNC:6871 Compounds that are ERK inhibitors Merck Sharp & Dohme Corp. 04/19/212D 3D TSV
US10759799 40 20 HGNC:4617 HGNC:3091 Indazole containing macrocycles and therapeutic uses thereof Samumed, LLC 04/19/212D 3D TSV
US10759813 222 220 HGNC:7154 Neprilysin inhibitors Theravance Biopharma R&D IP, LLC 04/19/212D 3D TSV
US10759812 26 15 HGNC:85 HGNC:84 Thienopyrimidine derivative and use thereof in medicine Sunshine Lake Pharma Co., Ltd. 04/19/212D 3D TSV
US10759793 318 106 2-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitors Almirall, S.A. 04/18/212D 3D TSV
US10759794 172 77 HGNC:6283 HGNC:6278 2-phenyl-3-(piperazinomethyl)imidazo[1,2-A]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders BAYER PHARMA AKTIENGESELLSCHAFT 04/18/212D 3D TSV
US10759787 43 33 Benzofuran derivative, preparation method thereof and use thereof in medicine Jiangsu Hengrui Medicine Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd. 04/18/212D 3D TSV
US10759796 139 138 CXCR4 inhibitors and uses thereof X4 PHARMACEUTICALS, INC. 04/18/212D 3D TSV
US10759792 26 26 CaMKII inhibitors and uses thereof The Johns Hopkins University 04/18/212D 3D TSV
US10759777 138 138 HGNC:8846 Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators Synchronicity Pharma, Inc. 04/18/212D 3D TSV
US10758530 28 20 HGNC:10435 HGNC:10431 HGNC:10430 HGNC:10432 Carboxamide derivatives useful as rsk inhibitors PHOENIX MOLECULAR DESIGNS 04/18/212D 3D TSV
US10759766 58 32 HGNC:6307 Certain chemical entities, compositions, and methods NEUPHARMA, INC. 04/18/212D 3D TSV
US10759769 46 46 HGNC:12524 Glucosylceramide synthase inhibitors for the treatment of diseases TBA 04/18/212D 3D TSV
US10759791 104 24 HGNC:7872 Mammalian and bacterial nitric oxide synthase inhibitors Northwestern University 04/18/212D 3D TSV
US10759788 6 2 HGNC:6251 HGNC:6255 Pharmaceutical uses of pyridine carboxamide derivatives JIANGSU HENGRUI MEDICINE CO., LTD.; SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. 04/18/212D 3D TSV
US10758542 530 232 HGNC:8031 HGNC:12440 Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors Array BioPharma Inc. 04/18/212D 3D TSV
US10758539 7 7 HGNC:6307 Therapeutic compounds and uses thereof Kala Pharmaceuticals, Inc. 04/18/212D 3D TSV
US10745383 8 8 1,3,5-triazine derivative and method of using same Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Lianyungang Runzhong Pharmaceutical Co., Ltd.; Centaurus Biopharma Co., Ltd. 04/13/212D 3D TSV
US10744128 140 66 HGNC:4617 HGNC:3091 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof Samumed, LLC 04/13/212D 3D TSV
US10744125 24 6 HGNC:268 HGNC:262 HGNC:263 HGNC:264 Adenosine A3 receptor modulators Palobiofarma, S.L. 04/13/212D 3D TSV
US10745392 57 19 HGNC:10593 HGNC:10585 HGNC:10596 Benzenesulfonamide compounds and their use as therapeutic agents Xenon Pharmaceuticals Inc. 04/13/212D 3D TSV
US10745401 582 190 HGNC:3023 HGNC:5286 Condensed lactam derivative SUMITOMO DAINIPPON PHARMA CO., LTD. 04/13/212D 3D TSV
US10745399 334 57 HGNC:8978 HGNC:795 HGNC:8975 HGNC:3942 HGNC:8977 HGNC:8976 Imidazolonylquinolines and the use thereof as ATM kinase inhibitors Merck Patent GmbH 04/13/212D 3D TSV
US10745388 16 16 HGNC:6863 Indazole compounds and uses thereof Incyte Corporation 04/13/212D 3D TSV
US10745380 2 2 HGNC:10894 Pyridine derivatives and their use in the treatment of cancer and hemoglobinopathies CTXT PTY LTD 04/13/212D 3D TSV
US10745410 18 18 Substituted [5,6]cyclic-4(3H)-pyrimidinones as anticancer agents ZENJI RESEARCH LABORATORIES 04/13/212D 3D TSV
US10745364 424 420 Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease Lycera Corporation; Merck Sharp & Dohme Corp. 04/13/212D 3D TSV
US10745420 101 96 Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase Board of Regents, The University of Texas System; ChemPartner Corporation 04/13/212D 3D TSV
US10744104 41 40 HGNC:7154 Neprilysin inhibitors Theravance Biopharma R&D IP, LLC 04/12/212D 3D TSV
US10744117 5 5 HGNC:9236 PPARG modulators for the treatment of osteoporosis The Scripps Research Institute; The University of Toledo 04/12/212D 3D TSV
US10752581 86 75 HGNC:429 HGNC:433 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase Eastern Virginia Medical School; The Regents of the University of California Santa; The United States of America Department of Health; Thomas Jefferson University 04/11/212D 3D TSV
US10752632 6 6 HGNC:7056 6-fluoro 2-methylbenzo[d]thiazol-5-yl compounds Eli Lilly and Company 04/11/212D 3D TSV
US10752598 20 20 Aryldiazepine derivatives as RSV inhibitors Enanta Pharmaceuticals, Inc. 04/11/212D 3D TSV
US10752616 136 46 HGNC:9864 HGNC:9866 HGNC:9865 Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists King''s College London 04/11/212D 3D TSV
US10752604 35 20 HGNC:11037 HGNC:11036 C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same Je II Pharmaceutical Co., Ltd. 04/11/212D 3D TSV
US10752613 21 15 HGNC:12805 HGNC:17989 Compounds and their use for reducing uric acid levels Acquist LLC 04/11/212D 3D TSV
US10752588 28 27 HGNC:3023 Dopamine D2 receptor ligands The Broad Institute, Inc.; Massachusetts Institute of Technology 04/11/212D 3D TSV
US10752623 196 62 HGNC:10593 HGNC:10585 HGNC:10596 Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors Xenon Pharmaceuticals Inc. 04/11/212D 3D TSV
US10752631 37 12 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Heterocyclic compounds as FGFR inhibitors Guangzhou Innocare Pharma Tech Co., Ltd. 04/11/212D 3D TSV
US10752626 25 25 Iso-citrate dehydrogenase (IDH) inhibitor SHANGHAI METON PHARMACEUTICAL CO., LTD 04/11/212D 3D TSV
US10752592 113 38 HGNC:8156 Morphan and morphinan analogues, and methods of use ALKERMES PHARMA IRELAND LIMITED 04/11/212D 3D TSV
US10752596 153 152 Nitrogen-containing heteroaryl compound and pharmaceutical use thereof JAPAN TOBACCO INC. 04/11/212D 3D TSV
US10751335 60 28 HGNC:8156 Signaling-biased mu opioid receptor agonists THE SCRIPPS RESEARCH INSTITUTE 04/11/212D 3D TSV
US10752615 526 148 HGNC:1133 HGNC:6171 HGNC:11719 HGNC:12434 Spirocyclic containing compounds and pharmaceutical uses thereof GB005, Inc. 04/11/212D 3D TSV
US10751339 55 14 HGNC:8979 HGNC:8978 HGNC:6251 Substituted aminopyrimidine compounds and methods of use SUNSHINE LAKE PHARMA CO., LTD.; CALITOR SCIENCES, LLC 04/11/212D 3D TSV
US10738015 84 42 HGNC:8155 HGNC:8156 1,3-diaza-spiro-[3.4]-octane derivatives GRÜNENTHAL GMBH 04/04/212D 3D TSV
US10738063 246 64 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds Pfizer Inc. 04/04/212D 3D TSV
US10738007 130 97 HGNC:10251 HGNC:10252 Amide compounds as kinase inhibitors, compositions and methods of treatment Translation Drug Development, LLC 04/04/212D 3D TSV
USRE48150 34 33 HGNC:6857 Apoptosis signal-regulating kinase inhibitors Gilead Sciences, Inc. 04/04/212D 3D TSV
US10736881 141 96 HGNC:4852 HGNC:13315 Benzimidazole derivatives: preparation and pharmaceutical applications MEI Pharma, Inc. 04/04/212D 3D TSV
US10738053 42 4 HGNC:1373 HGNC:10548 Bicyclic compounds as dual ATX/CA inhibitors Hoffmann-La Roche Inc. 04/04/212D 3D TSV
US10738048 152 37 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Bicyclic heterocycles as FGFR4 inhibitors Incyte Corporation 04/04/212D 3D TSV
US10738074 43 29 Cyclic di-nucleotide compounds as STING agonists Merck Sharp & Dohme Corp. 04/04/212D 3D TSV
US10738052 205 204 HGNC:7029 Imidazotriaines and imidazopyrimidines as kinase inhibitors INCYTE HOLDINGS CORPORATION; INCYTE CORPORATION 04/04/212D 3D TSV
US10738026 17 11 HGNC:10597 Isoquinoline derivatives and use thereof Purdue Pharma L.P. 04/04/212D 3D TSV
US10736890 75 37 HGNC:8156 Methods for treating depressive symptoms ALKERMES PHARMA IRELAND LIMITED 04/04/212D 3D TSV
US10738056 517 508 Pyrazolopyrimidinone compounds and uses thereof Aduro BioTech Inc. 04/04/212D 3D TSV
US10738009 160 158 HGNC:10582 Pyridone amides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED 04/04/212D 3D TSV
US10736974 64 35 HGNC:3788 Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy THE JOHNS HOPKINS UNIVERSITY 04/04/212D 3D TSV
US10738057 246 118 HGNC:8978 HGNC:8977 Tertiary alcohols as PI3K-γ inhibitors Incyte Corporation 04/04/212D 3D TSV
US10736883 326 315 HGNC:339 Triazole furan compounds as agonists of the APJ receptor AMGEN INC. 04/04/212D 3D TSV
US10723742 270 242 HGNC:29079 Biphenyl compound or salt thereof Taiho Pharmaceutical Co., Ltd. 03/30/212D 3D TSV
US10730902 10 5 HGNC:6561 HGNC:6563 1,1 ′-sulfanediyl-di-beta-D-galactopyranosides as inhibitors of galectins GALECTO BIOTECH AB 03/28/212D 3D TSV
US10730889 403 380 HGNC:30092 Amido spirocyclic amide and sulfonamide derivatives FORMA TM, LLC; Genentech, Inc. 03/28/212D 3D TSV
US10723734 237 230 HGNC:19679 Biaryl kinase inhibitors Bristol-Myers Squibb Company 03/28/212D 3D TSV
US10722495 51 51 HGNC:6863 Cyanoindazole compounds and uses thereof Incyte Corporation 03/28/212D 3D TSV
US10722597 33 4 HGNC:4852 HGNC:14065 HGNC:14064 HGNC:19086 HGNC:14063 HGNC:14068 HGNC:14067 HGNC:13315 HGNC:4854 HGNC:4853 HGNC:18128 Cyclodextrin-panobinostat adduct MIDATECH LTD. 03/28/212D 3D TSV
US10722489 10 10 HGNC:8923 D-3-phosphoglycerate dehydrogenase allosteric inhibitor and use thereof Peking University 03/28/212D 3D TSV
US10723705 206 204 HGNC:13315 Heterocyclic compounds and uses thereof Incyte Corporation 03/28/212D 3D TSV
US10723709 26 6 HGNC:2536 HGNC:2537 HGNC:2545 Protease inhibitors MEDIVIR AB 03/28/212D 3D TSV
US10723723 220 173 HGNC:6255 Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors Bristol-Myers Squibb Company 03/28/212D 3D TSV
US10730882 34 34 HGNC:10436 2-aminoquinazoline derivatives as P70S6 kinase inhibitors SENTINEL ONCOLOGY LIMITED 03/27/212D 3D TSV
US10730880 867 199 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors Array BioPharma Inc.; Celgene Corporation 03/27/212D 3D TSV
US10730877 3210 841 HGNC:15633 HGNC:15631 HGNC:15632 4-Azaindole compounds Bristol-Myers Squibb Company 03/27/212D 3D TSV
US10730868 104 95 HGNC:3540 Bicyclic heteroaryl substituted compounds Bristol-Myers Squibb Company 03/27/212D 3D TSV
US10730870 267 140 HGNC:12687 Compounds and methods for the enhanced degradation of targeted proteins ARVINAS OPERATIONS, INC.; YALE UNIVERSITY 03/27/212D 3D TSV
US10730865 49 49 Compounds for modulating aquaporins APOGLYX AB 03/27/212D 3D TSV
US10730860 3 2 HGNC:13575 Diaminopyrimidine benzenesulfone derivatives and uses thereof Dana-Farber Cancer Institute, Inc. 03/27/212D 3D TSV
US10730881 28 28 HGNC:620 Fused pyrimidine derivatives HOFFMANN-LA ROCHE, INC. 03/27/212D 3D TSV
US10730866 84 72 HGNC:10597 Indole derivatives and use thereof Purdue Pharma L.P. 03/27/212D 3D TSV
US10730874 328 296 HGNC:6371 Inhibitors of plasma kallikrein and uses thereof Shire Human Genetic Therapies, Inc. 03/27/212D 3D TSV
US10730875 135 31 HGNC:6190 HGNC:6192 HGNC:12440 Substituted imidazo[1,2-A]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof JN Therapeutics 03/27/212D 3D TSV
US10729680 63 63 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines BAYER PHARMA AKTIENGESELLSCHAFT 03/21/212D 3D TSV
US10730832 130 130 Aliphatic prolinamide derivatives ORION OPHTHALMOLOGY LLC 03/21/212D 3D TSV
US10729684 24 12 HGNC:10597 Alkynyl dihydroquinoline sulfonamide compounds AMGEN INC. 03/21/212D 3D TSV
US10729695 29 29 HGNC:320 Amino, amido and heterocyclic compounds as modulators of RAGE activity and uses thereof The Research Foundation for the State University of New York; New York University 03/21/212D 3D TSV
US10730856 12 12 HGNC:9596 Benzimidazole derivatives as EP4 ligands BAYER PHARMA AKTIENGESELLSCHAFT 03/21/212D 3D TSV
US10730849 95 51 Benzo[b]thiophene compounds as STING agonists Merck Sharp & Dohme Corp. 03/21/212D 3D TSV
US10730863 435 427 HGNC:7967 Bridged bicyclic compounds as farnesoid X receptor modulators Bristol-Myers Squibb Company 03/21/212D 3D TSV
US10729710 17 6 HGNC:3023 HGNC:3020 Catecholamine prodrugs for use in the treatment of Parkinson's disease H. Lundbeck A/S 03/21/212D 3D TSV
US10717746 178 86 HGNC:1780 Chemical compounds ASTRAZENECA AB 03/21/212D 3D TSV
US10730853 36 17 HGNC:5184 Compounds as neuronal histamine receptor-3 antagonists and uses thereof XW LABORATORIES INC. 03/21/212D 3D TSV
US10717737 116 115 HGNC:29079 Cyclopropylamines as LSD1 inhibitors Incyte Corporation 03/21/212D 3D TSV
US10717733 462 116 HGNC:6834 HGNC:550 HGNC:6666 Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof Pharmaxis Ltd. 03/21/212D 3D TSV
US10717734 176 44 HGNC:6834 HGNC:550 HGNC:6666 Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof Pharmaxis Ltd. 03/21/212D 3D TSV
US10716791 42 17 HGNC:18367 HGNC:18368 Inhibitors of peptidyl arginine deiminase (PAD) enzymes and uses thereof University Health Network 03/21/212D 3D TSV
US10730826 181 68 HGNC:2531 HGNC:2538 HGNC:2527 HGNC:2536 HGNC:2547 HGNC:2537 HGNC:2545 HGNC:2535 Ketone inhibitors of lysine gingipain CORTEXYME, INC. 03/21/212D 3D TSV
US10717708 62 31 HGNC:3827 HGNC:3826 Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists Bristol-Myers Squibb Company 03/21/212D 3D TSV
US10730850 106 106 HGNC:550 Pyridinylmethyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors Boehringer Ingelheim International GmbH 03/21/212D 3D TSV
US10717738 29 29 HGNC:3529 Pyrimidinone and its derivatives inhibiting factor XIa ONO PHARMACEUTICAL CO., LTD. 03/21/212D 3D TSV
US10717742 148 137 Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors Boehringer Ingelheim International GmbH 03/21/212D 3D TSV
US10730833 9 9 HGNC:348 Synthesis of diindolylmethanes and indolo[3,2-b]carbazoles, compounds formed thereby, and pharmaceutical compositions containing them Wisconsin Alumni Research Foundation 03/21/212D 3D TSV
US10730830 51 25 HGNC:3165 HGNC:14299 Tetrahydronaphthalene derivative ONO PHARMACEUTICAL CO., LTD. 03/21/212D 3D TSV
US10717764 402 207 Therapeutically active compounds and their methods of use Agios Pharmaceuticals, Inc. 03/21/212D 3D TSV
US10729691 118 59 HGNC:11005 Treatment of infectious diseases with glucose uptake inhibitors KADMON CORPORATION, LLC 03/21/212D 3D TSV
US10711036 87 87 HGNC:6819 MALT1 inhibitors and uses thereof Cornell University; Dana-Farber Cancer Institute, Inc.; Children''s Medical Center Corporation 03/15/212D 3D TSV
US10711006 65 28 HGNC:4840 HGNC:3697 HGNC:1057 HGNC:1133 HGNC:6193 HGNC:6171 HGNC:2444 HGNC:3765 Selective Bruton's tyrosine kinase inhibitor and use thereof HANGZHOU HERTZ PHARMACEUTICAL CO., LTD. 03/15/212D 3D TSV
US10711007 49 49 HGNC:10894 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) Prelude Therapeutics Incorporated 03/15/212D 3D TSV
US10711020 881 783 Tricyclic sulfones as RORγ modulators Bristol-Myers Squibb Company 03/15/212D 3D TSV
US10709688 40 16 HGNC:3559 HGNC:3557 Agent for treating synucleinopathy Tohoku University; National University Corporation Okayama University 03/14/212D 3D TSV
US10710980 616 88 Aminopyridine derivatives and their use as selective ALK-2 inhibitors Novartis AG 03/14/212D 3D TSV
US10709712 2614 1072 HGNC:9829 Biaryl amide compounds as kinase inhibitors NOVARTIS AG 03/14/212D 3D TSV
US10709695 2 2 Compounds as rearranged during transfection (RET) inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED 03/14/212D 3D TSV
US10709718 28 28 HGNC:2843 Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof Metabasis Therapeutics, Inc. 03/14/212D 3D TSV
US10710994 297 150 HGNC:497 Oxadiazole transient receptor potential channel inhibitors Genentech, Inc. 03/14/212D 3D TSV
US10711004 455 275 HGNC:497 Oxadiazole transient receptor potential channel inhibitors Genentech, Inc. 03/14/212D 3D TSV
US10710986 657 656 PD-1/PD-L1 inhibitors Gilead Sciences, Inc. 03/14/212D 3D TSV
US10710967 299 294 HGNC:9599 Pyrimidine derivative ASKA PHARMACEUTICAL CO., LTD. 03/14/212D 3D TSV
US10710978 234 59 HGNC:11403 HGNC:11408 HGNC:18174 HGNC:11406 STK4 inhibitors for treatment of hematologic malignancies DANA-FARBER CANCER INSTITUTE, INC.; FONDAZIONE CENTRO SAN RAFFAELE 03/14/212D 3D TSV
US10709719 42 10 HGNC:3167 HGNC:3165 Substituted bicyclic compounds Bristol-Myers Squibb Company 03/14/212D 3D TSV
US10709709 212 203 HGNC:10894 Substituted carbonucleoside derivatives useful as anticancer agents Pfizer Inc. 03/14/212D 3D TSV
US10676499 33 17 HGNC:3287 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA NOVARTIS AG 03/11/212D 3D TSV
US10676464 43 43 5-hydroxytryptamine receptor 7 activity modulators and their method of use Temple University Of The Commonwealth System of Higher Education 03/11/212D 3D TSV
US10676458 17 11 HGNC:4498 Antidiabetic bicyclic compounds Merch Sharp & Dohne Corp. Rahway 03/11/212D 3D TSV
US10676467 113 58 HGNC:3169 HGNC:3167 HGNC:3165 HGNC:14299 HGNC:3170 Compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof Washington University 03/11/212D 3D TSV
US10676457 130 129 HGNC:29079 Cyclopropylamines as LSD1 inhibitors Incyte Corporation 03/11/212D 3D TSV
US10676465 188 94 HGNC:4324 GLP-1 receptor agonists and uses thereof Pfizer Inc. 03/11/212D 3D TSV
US10676479 360 118 HGNC:17101 Imidazolepyridine compounds and uses thereof Novartis AG 03/11/212D 3D TSV
US10676470 36 34 Inhibitors of lysine gingipain CORTEXYME, INC. 03/11/212D 3D TSV
US10676469 383 182 HGNC:8154 HGNC:8156 Kappa opioid receptor antagonists and products and methods related thereto BLACKTHORN THERAPEUTICS, INC.; THE SCRIPPS RESEARCH INSTITUTE 03/11/212D 3D TSV
US10676485 106 53 HGNC:6943 Macrocyclic MCL-1 inhibitors and methods of use AbbVie Inc. 03/11/212D 3D TSV
US10676460 56 3 HGNC:9077 HGNC:11283 HGNC:11584 HGNC:14552 HGNC:17967 HGNC:12434 HGNC:11724 HGNC:6735 HGNC:2451 HGNC:5465 HGNC:4617 HGNC:2459 HGNC:6112 HGNC:2457 HGNC:3767 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:6171 HGNC:11390 HGNC:12440 HGNC:1079 HGNC:1771 HGNC:1133 HGNC:6860 HGNC:7972 HGNC:6524 HGNC:1775 Quinazolines as potassium ion channel inhibitors Bristol-Myers Squibb Company 03/11/212D 3D TSV
US10676476 30 14 HGNC:3430 HGNC:5253 Small-molecule HSP90 inhibitors Sloan-Kettering Institute for Cancer Research 03/11/212D 3D TSV
US10676446 190 190 HGNC:3357 Bicyclic quinazolinone derivatives Hoffmann-La Roche Inc. 03/10/212D 3D TSV
US10676434 200 178 HGNC:1133 Carbazole derivatives Bristol-Myers Squibb Company 03/10/212D 3D TSV
US10675286 612 109 HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 Heterocyclic compounds and uses thereof Infinity Pharmaceuticals, Inc. 03/10/212D 3D TSV
US10676433 355 196 HGNC:5992 HGNC:8537 Indole derivatives and their use in neurodegenerative diseases Merck Patent GmbH 03/10/212D 3D TSV
US10676438 16 10 HGNC:6251 KCNQ2-5 channel activator Ono Pharmaceutical Co., Ltd. 03/10/212D 3D TSV
US10676431 270 127 HGNC:3827 HGNC:3826 Phenylpyrrolidinone formyl peptide 2 receptor agonists Bristol-Myers Squibb Company 03/10/212D 3D TSV
US10675268 284 169 HGNC:11330 HGNC:11331 HGNC:11334 HGNC:11332 HGNC:11333 Somatostatin receptor subtype 4 (SSTR4) agonists Centrexion Therapeutics Corporation 03/10/212D 3D TSV
US10675284 37 37 HGNC:6190 HGNC:8977 Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors Incyte Corporation 03/10/212D 3D TSV
US10703751 36 7 HGNC:6192 HGNC:6193 Amino-imidazopyridine derivatives as Janus kinase inhibitors and pharmaceutical use thereof Leo Pharma A/S 03/08/212D 3D TSV
US10703741 26 16 HGNC:18368 Covalent inhibitors of PAD4 Padlock Therapeutics, Inc. 03/08/212D 3D TSV
US10702504 21 21 HGNC:11812 Degradation of tripartite motif-containing protein 24 (TRIM24) by conjugation of TRIM24 inhibitors with E3 ligase ligand and methods of use DANA-FARBER CANCER INSTITUTE, INC. 03/08/212D 3D TSV
US10703733 457 445 MCL-1 inhibitors Gilead Sciences, Inc. 03/08/212D 3D TSV
US10702498 27 15 HGNC:8154 HGNC:8156 MU opioid receptor modulators THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; FRIEDRICH-ALEXANDER-UNIVERSITAT ERLANGEN-NÜRNBERG; THE BOARD OF TRUSTEES OFTHE LELAND STANFORD JUNIOR UNIVERSITY; THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 03/08/212D 3D TSV
US10703749 843 289 HGNC:8537 P2X7 modulators Janssen Pharmaceutica NV 03/08/212D 3D TSV
US10708263 5 1 Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders GALAPAGOS NV 03/08/212D 3D TSV
US10703740 14 14 HGNC:13575 Substituted benzimidazoles, their preparation and their use as pharmaceuticals Neomed Institute 03/08/212D 3D TSV
US10703755 351 337 HGNC:15631 Substituted purine derivative SUMITOMO DAINIPPON PHARMA CO., LTD. 03/08/212D 3D TSV
US10696692 374 308 HGNC:30092 Amido-benzyl sulfone and sulfoxide derivates TBA 03/02/212D 3D TSV
US10696672 157 152 HGNC:6161 Amino acid compounds and methods of use Pliant Therapeutics, Inc. 03/02/212D 3D TSV
US10696682 44 44 HGNC:1771 CDK inhibitors G1 Therapeutics, Inc. 03/02/212D 3D TSV
US10696661 70 69 HGNC:11305 Compounds Exonate Limited 03/02/212D 3D TSV
US10696638 48 43 HGNC:10251 HGNC:10252 Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE 03/02/212D 3D TSV
US10695334 98 57 HGNC:6371 HGNC:11830 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors Boehringer Ingelheim International GmbH 03/02/212D 3D TSV
US10696678 154 64 HGNC:1722 Kinase inhibitor, and preparing method and pharmaceutical use thereof GAN & LEE PHARMACEUTICALS 03/02/212D 3D TSV
US10696665 61 23 HGNC:5382 Mutant IDH1 inhibitors Eli Lilly and Company 03/02/212D 3D TSV
US10695337 794 388 Piperidin-4-yl azetidine derivatives as JAK1 inhibitors Incyte Holdings Corporation; Incyte Corporation 03/02/212D 3D TSV
US10695347 84 40 HGNC:427 Pyrimidine derivative and use thereof HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. 03/02/212D 3D TSV
US10696660 91 36 HGNC:10251 HGNC:10252 Rho kinase inhibitors Kadmon Corporation, LLC 03/02/212D 3D TSV
US10696689 23 23 HGNC:11331 Somatostatin modulators and uses thereof CRINETICS PHARMACEUTICALS, INC. 03/02/212D 3D TSV
US10696655 125 125 HGNC:2348 Therapeutic compounds and uses thereof GENENTECH, INC.; CONSTELLATION PHARMACEUTICALS, INC. 03/02/212D 3D TSV
US10689373 308 149 HGNC:4849 HGNC:4848 1,2-substituted cyclopentanes as orexin receptor antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED 02/22/212D 3D TSV
US10689345 273 269 1-cyano-pyrrolidine compounds as USP30 inhibitors Mission Therapeutics Limited 02/22/212D 3D TSV
US10689401 50 25 HGNC:934 HGNC:933 C5-C6-oxacyclic fused iminothiazine dioxide compounds bearing an ether linker as BACE inhibitors, compositions, and their use Merck Sharp & Dohme Corp. 02/22/212D 3D TSV
US10689705 212 71 HGNC:3690 HGNC:3689 HGNC:3688 FGFR3 fusion gene and pharmaceutical drug targeting same Chugai Seiyaku Kabushiki Kaisha 02/22/212D 3D TSV
US10689346 302 246 HGNC:6371 Human plasma kallikrein inhibitors BioCryst Pharmaceuticals, Inc. 02/22/212D 3D TSV
US10688100 52 13 HGNC:10261 Macrocylic compounds as ROS1 kinase inhibitors Array BioPharma Inc. 02/22/212D 3D TSV
US10688093 708 647 HGNC:4037 Methods, compositions, and uses of novel Fyn kinase inhibitors TBA 02/22/212D 3D TSV
US10689357 43 43 HGNC:736 N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and use thereof NORTHEASTERN UNIVERSITY 02/22/212D 3D TSV
US10689398 91 89 HGNC:8157 OXA-Diazaspiro compounds having activity against pain ESTEVE PHARMACEUTICALS, S.A. 02/22/212D 3D TSV
USRE48059 122 64 Piperazine-substituted benzothiophenes for treatment of mental disorders Otsuka Pharmaceutical Co., Ltd. 02/22/212D 3D TSV
US10689327 30 15 HGNC:4595 HGNC:4594 Prodrug amino acid derivative TAISHO PHARMACEUTICAL CO., LTD. 02/22/212D 3D TSV
US10689339 69 69 HGNC:2545 Pyrrolidine derivatives Hoffmann-La Roche Inc. 02/22/212D 3D TSV
US10689362 508 124 HGNC:8804 HGNC:6342 HGNC:3765 Quinoxaline compounds as type III receptor tyrosine kinase inhibitors Development Center for Biotechnology 02/22/212D 3D TSV
US10689399 23 23 HGNC:9213 Substituted 3,4,5,6,8,10,14,14a-octahydro-2h-2,6-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazocines and methods for treating viral infections Gilead Sciences, Inc. 02/22/212D 3D TSV
US10689369 149 127 Substituted indazole compounds as RORgammaT inhibitors and uses thereof Merck Sharp & Dohme Corp. 02/22/212D 3D TSV
US10689376 39 39 HGNC:3356 Substituted-3H-imidazo [4,5-c] pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics Stingray Therapeutics, Inc.; The University of Utah 02/22/212D 3D TSV
US10689414 404 206 Therapeutically active compounds and their methods of use Agios Pharmaceuticals, Inc. 02/22/212D 3D TSV
US10689367 327 233 HGNC:339 Triazole pyridyl compounds as agonists of the APJ receptor AMGEN INC. 02/22/212D 3D TSV
US10689390 18 18 HGNC:13575 Tricyclic fused derivatives of 1-(cyclo)alkyl pyridin-2-one useful for the treatment of cancer JUBILANT BIOSYS LIMITED 02/22/212D 3D TSV
US10689395 14 14 HGNC:13575 Tricyclic fused pyridin-2-one derivatives and their use as BRD4 inhibitors JUBILANT BIOSYS LIMITED 02/22/212D 3D TSV
US10669240 500 242 HGNC:3091 5-substituted indazole-3-carboxamides and preparation and use thereof Samumed, LLC 02/21/212D 3D TSV
US10669246 153 115 HGNC:8803 HGNC:76 HGNC:6342 Benzothiazol compounds and methods using the same for treating neurodegenerative disorders 1ST Biotherapeutics, Inc. 02/21/212D 3D TSV
US10669268 343 306 HGNC:10548 Bicyclic derivatives Hoffmann-La Roche Inc. 02/21/212D 3D TSV
US10669289 209 104 HGNC:9542 HGNC:9545 Boronic acid derivatives MERCK PATENT GMBH 02/21/212D 3D TSV
US10669245 37 37 HGNC:2528 Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides dipeptidyl peptidase 1 inhibitors ASTRAZENECA AB 02/21/212D 3D TSV
US10669285 43 43 HGNC:10548 Condensed [1,4] diazepine compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors Hoffmann-La Roche Inc. 02/21/212D 3D TSV
US10669276 48 48 Fused pyrimidine derivatives HOFFMANN-LA ROCHE INC. 02/21/212D 3D TSV
US10669271 94 30 HGNC:7794 HGNC:9644 Heterocyclic compounds as immunomodulators Incyte Corporation 02/21/212D 3D TSV
US10669279 372 104 HGNC:8780 HGNC:8781 HGNC:8783 Imidazopyridazine compounds Pfizer Inc. 02/21/212D 3D TSV
US10669243 10 10 Isoxazole carboxamides as irreversible SMYD inhibitors EPIZYME, INC. 02/21/212D 3D TSV
US10669296 8 4 LXR agonists and uses thereof Rgenix, Inc. 02/21/212D 3D TSV
US10669265 142 72 HGNC:6307 HGNC:8804 HGNC:9437 Pyridyl benzothiophenes as kinase inhibitors ALLERGAN, INC. 02/21/212D 3D TSV
US10669267 65 39 HGNC:8537 Substituted N-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide and N-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide derivatives P2X7 receptor antagonists Axxam S.P.A. 02/21/212D 3D TSV
US10669273 42 36 HGNC:6059 Use of aza-tryptanthrin derivatives as inhibitors of IDO1 and/or TDO Peking University 02/21/212D 3D TSV
US10683294 67 67 HGNC:1338 5-5 fused rings as C5a inhibitors ChemoCentryx, Inc. 02/16/212D 3D TSV
US10683295 59 29 HGNC:11526 HGNC:6251 HGNC:11527 HGNC:11528 Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-A]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof Ogeda SA 02/16/212D 3D TSV
US10683291 3 3 HGNC:3165 Heterocyclic compounds for the treatment of disease OPPILAN PHARMA LTD. 02/16/212D 3D TSV
US10683290 84 80 Tricyclic compounds as anticancer agents Bristol-Myers Squibb Company 02/16/212D 3D TSV
US10683309 84 42 HGNC:12008 HGNC:20692 Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN; FORSCHUNGSVERBUND BERLIN E.V. 02/16/212D 3D TSV
US10668071 105 100 (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use BAYER PHARMA AKTIENGESELLSCHAFT 02/15/212D 3D TSV
US10667515 17 17 (S)-5-ethynyl-anabasine, derivatives thereof, and related compositions and methods of making and using Iowa State University Research Foundation, Inc. 02/15/212D 3D TSV
US10683279 71 68 HGNC:6857 Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof Enanta Pharmaceuticals, Inc. 02/15/212D 3D TSV
US10683289 23 23 HGNC:6857 Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof Enanta Pharmaceuticals, Inc. 02/15/212D 3D TSV
US10682352 117 100 HGNC:5382 Compound having mutant IDH inhibitory activity, preparation method and use thereof SHANGHAI HAIHE PHARMACEUTICAL CO., LTD.; SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES 02/15/212D 3D TSV
US10669227 24 9 HGNC:7175 HGNC:7176 HGNC:7166 HGNC:7159 Curcumin analogues as zinc chelators and their uses THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK 02/15/212D 3D TSV
US10669234 193 147 HGNC:12513 Cyanopyrrolidines as dub inhibitors for the treatment of cancer MISSION THERAPEUTICS LIMITED 02/15/212D 3D TSV
US10668167 176 62 HGNC:7978 HGNC:644 HGNC:3467 HGNC:8910 Glucocorticoid receptor agonist and immunoconjugates thereof AbbVie Inc. 02/15/212D 3D TSV
US10683287 96 45 HGNC:934 HGNC:933 Heterocyclic derivatives and their use in the treatment of neurological disorders Novartis AG 02/15/212D 3D TSV
US10669235 336 55 HGNC:8803 HGNC:3763 HGNC:6307 HGNC:8804 HGNC:3690 HGNC:3688 Indole derivatives and their use as protein kinase inhibitors RESPIVERT LIMITED 02/15/212D 3D TSV
US10668051 56 56 HGNC:25896 Modulators of calcium release-activated calcium channel RHIZEN PHARMACEUTICALS SA 02/15/212D 3D TSV
US10668033 4 4 HGNC:9602 Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto ARENA PHARMACEUTICALS, INC. 02/15/212D 3D TSV
US10668067 135 135 HGNC:10597 Pyridine sulfonamides AMGEN INC. 02/15/212D 3D TSV
US10668094 92 21 Selective inhibitors of Alpha2-containing isoforms of Na,K-ATPase and use thereof for reduction of intraocular pressure Yeda Research and Development Co. Ltd. 02/15/212D 3D TSV
US10669239 74 68 HGNC:8031 Tetrahydronaphthyl urea derivative MOCHIDA PHARMACEUTICAL CO., LTD. 02/15/212D 3D TSV
US10660877 2542 841 HGNC:15633 HGNC:15631 HGNC:15632 Pyridyl substituted indole compounds Bristol-Myers Squibb Company 02/08/212D 3D TSV
US10662159 204 60 HGNC:3553 HGNC:17038 HGNC:21398 ABHD6 and dual ABHD6/MGL inhibitors and their uses MAKSCIENTIFIC, LLC 02/07/212D 3D TSV
US10660876 90 89 HGNC:2771 Amino compounds for treatment of medical disorders Achillion Pharmaceuticals, Inc. 02/07/212D 3D TSV
US10662184 150 83 HGNC:10593 HGNC:10585 HGNC:10596 Benzenesulfonamide compounds and their use as therapeutic agents Xenon Pharmaceuticals Inc. 02/07/212D 3D TSV
US10660898 27 27 HGNC:8972 Benzimidazole derivatives as PI3 kinase inhibitors GLAXOSMITHKLINE LLC 02/07/212D 3D TSV
US10662187 134 124 HGNC:6735 HGNC:1057 HGNC:1133 HGNC:3236 HGNC:6524 Bruton's tyrosine kinase inhibitors Zibo Biopolar Changsheng Pharmaceutical Co. Ltd.; Shanghai Institute of Materia Medica, Chinese Academy of Sciences 02/07/212D 3D TSV
US10662156 94 90 HGNC:6819 Guanidine derivative and medical use thereof Toray Industries, Inc. 02/07/212D 3D TSV
US10662189 84 78 HGNC:8781 PDE4 inhibitor SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT CO., LTD. 02/07/212D 3D TSV
US10662186 650 137 HGNC:1780 HGNC:1771 HGNC:1778 HGNC:1722 HGNC:1777 HGNC:1774 HGNC:1773 Substituted pyrimidines as cyclin-dependent kinase inhibitors SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. 02/07/212D 3D TSV
US10654833 96 90 HGNC:6857 ASK1 isoindolin-1-one inhibitors and methods of use thereof Hepatikos Therapeutics, LLC 02/01/212D 3D TSV
US10654857 68 7 HGNC:10555 Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors Hoffman-La Roche Inc. 02/01/212D 3D TSV
US10654835 207 69 Compounds and methods for inhibiting JAK Dizal (Jiangsu) Pharmaceutical Co., Ltd. 02/01/212D 3D TSV
US10654856 20 17 HGNC:15631 HGNC:15632 Method for preparing pyrrolo[3,2-D]pyrimidine compound, and intermediates thereof CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. 02/01/212D 3D TSV
US10654855 73 73 HGNC:391 Protein kinase B inhibitors AstraZeneca AB 02/01/212D 3D TSV
US10654836 40 10 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Pyrimidine derivative, method for preparing same and use thereof in medicine Zhejiang Hisun Pharmaceutical Co., Ltd. 02/01/212D 3D TSV
US10654866 44 21 HGNC:3467 Selective estrogen receptor degraders Eli Lilly and Company 02/01/212D 3D TSV
US10654853 147 145 Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors MISSION THERAPEUTICS LIMITED 02/01/212D 3D TSV
US10654860 35 31 HGNC:10252 Tricyclic rho kinase inhibitors Bristol-Myers Squibb Company 02/01/212D 3D TSV
US10653688 302 143 HGNC:4617 HGNC:3091 6-(6-membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof Samumed, LLC 01/31/212D 3D TSV
US10654831 85 14 HGNC:1780 HGNC:1771 HGNC:1774 HGNC:1773 HGNC:1775 Antiproliferative pyrimidine-based compounds G1 Therapeutics, Inc. 01/31/212D 3D TSV
US10654814 240 127 HGNC:4852 HGNC:14064 HGNC:13315 HGNC:4854 HGNC:4853 Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity KANCERA AB 01/31/212D 3D TSV
US10653701 103 52 HGNC:6307 HGNC:1133 HGNC:6193 HGNC:3689 HGNC:3236 HGNC:3688 Substituted quinazolines for inhibiting kinase activity NEUPHARMA, INC. 01/31/212D 3D TSV
US10647665 39 33 Biaryl urea derivative or salt thereof and preparation process and use for the same Fudan University 01/25/212D 3D TSV
US10647719 107 5 HGNC:10555 HGNC:1373 Bicyclic compounds as dual ATX/CA inhibitors Hoffmann-La Roche Inc. 01/25/212D 3D TSV
US10647706 40 14 HGNC:6026 HGNC:6027 Chemokine CXCR1 and CXCR2 receptor antagonist compounds, and use thereof in the treatment of chemokine-mediated pathologies GALDERMA RESEARCH & DEVELOPMENT 01/25/212D 3D TSV
US10647694 45 40 HGNC:427 Diphenylaminopyrimidine and triazine compound, and pharmaceutical composition and use thereof ARROMAX PHARMATECH CO., LTD. 01/25/212D 3D TSV
US10647700 14 14 EZH2 inhibitor and use thereof TARAPEUTICS SCIENCE INC. 01/25/212D 3D TSV
US10646575 3 3 HGNC:2717 Heterocyclic degronimers for target protein degradation C4 Therapeutics, Inc. 01/25/212D 3D TSV
US10646492 366 342 HGNC:8977 Heterocyclylamines as PI3K inhibitors Incyte Corporation; Incyte Holdings Corporation 01/25/212D 3D TSV
US10647720 614 333 HGNC:6192 HGNC:11491 Pyrimido-pyridazinone compounds and methods of use thereof Asan BioSciences, LLC 01/25/212D 3D TSV
US10647727 66 47 Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors Merck Sharp & Dohme Corp. 01/25/212D 3D TSV
US10647686 82 50 HGNC:11396 HGNC:11395 Substituted pyrimidines for preventing or treating cancer and inflammatory diseases KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY 01/25/212D 3D TSV
US10647713 620 601 TYK2 inhibitors and uses thereof Nimbus Lakshmi, Inc. 01/25/212D 3D TSV
US10647708 46 46 HGNC:10894 Tetrahydroisoquinoline derived PRMT5-inhibitors CTXT PTY. LTD 01/25/212D 3D TSV
US10639286 194 172 Alkoxy compounds for disease treatment ACUCELA INC. 01/18/212D 3D TSV
US10640498 69 68 Compounds MISSION THERAPEUTICS LIMITED 01/18/212D 3D TSV
US10640533 114 19 HGNC:2524 HGNC:24059 HGNC:9537 Epoxyketone compounds for enzyme inhibition CENTRAX INTERNATIONAL, INC. 01/18/212D 3D TSV
US10640486 86 85 HGNC:1133 Heteroarylcarboxamide